artenimol profile

artenimol: derivative of antimalarial drug artemisinin (quinghaosu) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11358077
CHEMBL ID	511326
CHEBI ID	168754
SCHEMBL ID	18744731
MeSH ID	M0117179
PubMed CID	456410
CHEMBL ID	307261
SCHEMBL ID	2132158
MeSH ID	M0117179
PubMed CID	10221470
CHEMBL ID	252518
SCHEMBL ID	19937859
MeSH ID	M0117179

Synonym
(1r,4s,5r,8s,9r,10r,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
CHEBI:168754
(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-ol
(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3,-j)-1,2-benzodioxepin-10-ol
x0uiv26abx ,
nsc 758682
unii-x0uiv26abx
dtxsid5045962 ,
nsc-758682
(1r,4s,5r,8s,9r,10r,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-ol
artenimol [inn]
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3r-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.beta.,12.beta.,12ar*))-
.alpha.-dihydroartemisinin
dihydroartimisinin
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3r,5as,6r,8as,9r,10r,12r,12ar)-
S2290
(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10-ol
AKOS022168199
Q-100792
SCHEMBL18744731
alpha-dihydroartemisinin
NCGC00346590-02
123930-80-3
CCG-267307
Q27293233
(1s,4s,5r,8s,9r,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
dhqhs 1; -dihydroartemisinin
CHEMBL511326
(1r,4s,5r,8s,9r,10r,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,??.0?,??]hexadecan-10-ol
EN300-7407671
AC-2067
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))-
D07362
artenimol (inn)
dihydroquinghoasu
jav-110
vm3352
[3r-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12ar*)]-decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4.3-j]-1,2-benzodioxepin
D3793
SCHEMBL2132158
CHEMBL307261 ,
AKOS015962875
unii-6a9o50735x
beta-dihydroartemisinin
dhqhs 2
artemisinin, dihydro
dihydroartemisinin + proveblue
AKOS026749923
BJDCWCLMFKKGEE-KXTPALSWSA-N
bdbm50578409
(4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,.0?,]hexadecan-10-ol
EN300-27122030
PD087060
artenimol
dihydroqinghaosu
cotexin
cotecxin
dihydroartemisinine
alaxin
salaxin
santecxin
artenimolum
di-hydroqinghaosu
.beta.-dihydroartemisinin
dihydroartemisinin, .beta.-
CHEMBL252518
dynamax
(1s,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-ol
(1s,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
SCHEMBL19937859
EN300-19873907
1279039-00-7
FS-7037

Excerpt	Reference	Relevance
" This selective uptake may explain why the artemisinin derivatives are selectively toxic to malaria parasites."	( Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Hossler, P; Kamchonwongpaisan, S; McKeever, P; Meshnick, SR; Ziffer, H, 1997)	0.3
" In this assay, dihydroartemisinin is significantly more toxic than artemether or arteether."	( In vitro neurotoxicity of artemisinin derivatives. McLean, WG; Ward, SA, 1998)	0.3
" These data indicate that once and twice daily oral administration of artemether, artesunate and dihydroartemisinin is relatively safe when compared to intramuscular administration of the oil-based compounds."	( Assessment of the neurotoxicity of oral dihydroartemisinin in mice. Looareesuwan, S; Nontprasert, A; Prakongpan, S; Pukrittayakamee, S; Supanaranond, W; White, NJ, )	0.13
"Artekin is safe and effective combination therapy for uncomplicated malaria in children and adults."	( Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Davis, TM; Denis, MB; Hung, TY; Ilett, KF; Karunajeewa, H; Lim, C; Socheat, D, 2004)	0.32
" Adverse events and clinical and parasitological outcomes were recorded."	( Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; van Geertruyden, JP; van Overmeir, C, 2006)	0.33
" We found dihydroartemisinin (5-25 microM) inhibited the growth and induced apoptosis of C6 cells in a concentration- and time-dependent manner; however, it was much less toxic to rat primary astrocytes."	( Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. Huang, XJ; Lu, YB; Ma, ZQ; Wei, EQ; Zhang, WP, 2007)	0.34
"Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria."	( Efficacy and safety of dihydroartemisinin-piperaquine. Ashley, EA; Day, NP; Myint, HY; Nosten, F; White, NJ, 2007)	0.34
" Adverse events were monitored and laboratory parameters on study Days 0, 2, 5, and 7 post drug administrations were analyzed."	( Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. Atipas, S; Chatsiricharoenkul, S; Kaewkungwal, J; Khuhapinant, A; Kongpatanakul, S, 2009)	0.35
" All adverse events were mild."	( Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. Atipas, S; Chatsiricharoenkul, S; Kaewkungwal, J; Khuhapinant, A; Kongpatanakul, S, 2009)	0.35
" Participants were actively monitored for adverse events for 28 days and then passively for up to 63 days after treatment."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.35
" Most adverse events were rare, with only cough, diarrhoea, vomiting, and anaemia occurring in more than 1% of treatments."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.35
"Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children."	( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009)	0.35
"04), there were no differences between treatment arms in the occurrence of adverse events."	( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011)	0.37
"DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed."	( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011)	0.37
" Few and mild adverse events were reported."	( Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Amansyah, F; Dedang, TA; Driyah, S; Ekowatiningsih, R; Hasugian, AR; Januar, L; Labora, J; Prasetyorini, B; Purnama, A; Purnamasari, T; Salwati, E; Siswantoro, H; Tjitra, E; Wijayanto, B; Yusnita, EA; Yuwarni, E, 2012)	0.38
"AN and DHP are confirmed very effective, safe and tolerate for treatment of any malaria."	( Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Amansyah, F; Dedang, TA; Driyah, S; Ekowatiningsih, R; Hasugian, AR; Januar, L; Labora, J; Prasetyorini, B; Purnama, A; Purnamasari, T; Salwati, E; Siswantoro, H; Tjitra, E; Wijayanto, B; Yusnita, EA; Yuwarni, E, 2012)	0.38
" Both DP and A + M were well tolerated, with the majority of adverse events of mild or moderate severity."	( Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Bacchieri, A; Bhattacharyya, PC; Corsi, M; Dev, V; Dubashi, N; Gargano, N; Ghosh, SK; Kumar, A; Rao, BH; Srivastava, B; Tommasini, S; Ubben, D; Valecha, N, 2012)	0.38
" No neurological or cardiac toxicity was observed and seven dogs exhibited no adverse effects at all."	( Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Efferth, T; Erich, SA; Fleckenstein, L; Grinwis, GC; London, CA; Mol, JA; Rutteman, GR; Spee, B, 2013)	0.39
" No serious adverse event was noted during the study period."	( Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. Abiola, A; Faye, B; Folly, K; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, LA; Ndiaye, M; Sow, D; Sylla, K; Tine, RC, 2013)	0.39
"In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs."	( Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. Abiola, A; Faye, B; Folly, K; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, LA; Ndiaye, M; Sow, D; Sylla, K; Tine, RC, 2013)	0.39
" Incidence of adverse events was related to underlying disease; malaria being reported in both treatment arms."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Akhwale, W; Eyase, F; Johnson, JD; Juma, E; Koskei, N; Obonyo, C; Ogutu, BR; Omollo, R; Omondi, EK; Ongecha, JM; Onyango, KO; Otieno, GA; Otieno, L; Perkins, DJ, 2014)	0.4
" Both ACT regimens were safe and well tolerated."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
"Treatment of uncomplicated malaria with AL or DP was efficacious and safe in HIV-infected children taking ART."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
"9% of side reaction with 7 cases suffering from mild adverse responses among 71 of full-course medication."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.37
"DHAPIP is efficacious and safe for the treatment of uncomplicated falciparum malaria in Laiza city of Myanmar in the border area."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.37
" Even without a clear synergistic interaction, the combination of DHA and SS provides a safe and affordable form of cancer treatment."	( Additive cytotoxic effects of dihydroartemisinin and sodium salicylate on cancer cells. Singh, NP; Wickerath, M, 2014)	0.4
" There were no differences between the study arms in the incidence of serious adverse events during the intervention and the incidence of malaria during the 1-y period after the intervention was stopped."	( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014)	0.4
" No statistical significant differences were observed in the occurrence of adverse events among treatment groups."	( Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015)	0.42
" Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs)."	( Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Abdulla, S; Adjei, A; Adjuik, M; Akparibo, R; Baiden, R; Binka, F; Compaoré, G; Gyapong, M; Halidou, T; Macete, E; Mulokozi, A; Oduro, A; Ogutu, B; Osei, I; Owusu-Agyei, S; Sevene, E; Sie, A; Smith, P; Upunda, GL; Valea, I; Yawson, A, 2015)	0.42
" Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®."	( Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Abdulla, S; Adjei, A; Adjuik, M; Akparibo, R; Baiden, R; Binka, F; Compaoré, G; Gyapong, M; Halidou, T; Macete, E; Mulokozi, A; Oduro, A; Ogutu, B; Osei, I; Owusu-Agyei, S; Sevene, E; Sie, A; Smith, P; Upunda, GL; Valea, I; Yawson, A, 2015)	0.42
" The primary endpoint was the PCR-corrected adequate clinical and parasitological response (ACPR) at day 28 (D28); the secondary endpoints included ACPR at D42, clearance times for parasites, fever, and gametocytes, and the incidence of adverse events."	( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]. Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, )	0.13
" The combinations were well tolerated, with no serious adverse events reported during the follow-up period."	( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]. Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, )	0.13
" Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP."	( Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Dorsey, G; Gutman, J; Kovacs, S; Stergachis, A; Ter Kuile, FO, 2017)	0.46
" Moreover, in mice, ARS4 inhibited growth and intraperitoneal dissemination and metastasis of ovarian cancer cells without observable toxic effects."	( Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer. Ba, Q; Chen, K; Chen, T; Li, J; Li, X; Liu, H; Liu, Y; Wang, H; Zhang, X; Zhou, Y, 2016)	0.43
"Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are licensed and deployed."	( Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. Adjei, A; Adjuik, M; Baiden, R; Binka, F; Gyapong, M; Oduro, AR; Osei, I; Owusu-Agyei, S; Sobe, E; Yawson, A, 2017)	0.46
" There were nine adverse events of special interest (AESI); itching/pruritus (7), dizziness (1), and skin lesions (1)."	( Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. Adjei, A; Adjuik, M; Baiden, R; Binka, F; Gyapong, M; Oduro, AR; Osei, I; Owusu-Agyei, S; Sobe, E; Yawson, A, 2017)	0.46
" Dizziness, nausea, vomiting, headache and asthenia as adverse events (AEs) were more common in MQAS than in AL or DHAPQ (p < 0."	( Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria. Buyze, J; D'Alessandro, U; Hachizovu, S; Kabuya, JB; Kasongo, W; Mulenga, J; Mulenga, M; Mwakazanga, D; Nambozi, M; Van Geertruyden, JP, 2017)	0.46
" Its adverse effects are generally tolerable and temporary."	( Choreoathetosis - an unusual adverse effect of dihydroartemisinin-piperaquine: a case report. Kadia, BM; Morfaw, C; Simo, ACG, 2017)	0.46
"Although dihydroartemisinin-piperaquine is increasingly popular as a well-tolerated/efficacious antimalarial drug, clinicians must note the rare possibility of choreoathetosis as an adverse effect of this medication and educate patients accordingly."	( Choreoathetosis - an unusual adverse effect of dihydroartemisinin-piperaquine: a case report. Kadia, BM; Morfaw, C; Simo, ACG, 2017)	0.46
" However, whether DHA has adverse effects on oocyte maturation is unknown."	( Toxicity and related mechanisms of dihydroartemisinin on porcine oocyte maturation in vitro. Che, MJ; Fu, XW; Hou, YP; Liu, C; Liu, HG; Luo, Y, 2018)	0.48
" After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)."	( Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018)	0.48
" Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA."	( A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. Ali, AS; Ali, SM; Aydin-Schmidt, B; Bennett, A; Björkman, A; Hodzic, L; Islam, A; Jovel, I; Khamis, M; Magnusson, E; Mårtensson, A; Mkali, H; Morris, U; Msellem, MI; Poirot, E; Sachs, MC; Shija, SJ; Tarning, J, 2018)	0.48
" Adverse events were reported in 11."	( A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. Ali, AS; Ali, SM; Aydin-Schmidt, B; Bennett, A; Björkman, A; Hodzic, L; Islam, A; Jovel, I; Khamis, M; Magnusson, E; Mårtensson, A; Mkali, H; Morris, U; Msellem, MI; Poirot, E; Sachs, MC; Shija, SJ; Tarning, J, 2018)	0.48
"Plasmodium falciparum and Plasmodium vivax infections are important causes of adverse pregnancy outcomes in the Asia-Pacific region."	( Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la Adams, ER; Ahmed, R; Asih, PBS; Chen, T; Faragher, B; Khairallah, C; Lukito, T; Maratina, SS; Pace, C; Poespoprodjo, JR; Price, RN; Santana-Morales, MA; Smedley, J; Syafruddin, D; Ter Kuile, FO; Unwin, VT; Wang, D; Williams, CT, 2019)	0.51
" Conditions related to the pregnancy, the puerperium, and the perinatal period were the most common serious adverse events for the mothers, and infections and infestations for the infants."	( Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la Adams, ER; Ahmed, R; Asih, PBS; Chen, T; Faragher, B; Khairallah, C; Lukito, T; Maratina, SS; Pace, C; Poespoprodjo, JR; Price, RN; Santana-Morales, MA; Smedley, J; Syafruddin, D; Ter Kuile, FO; Unwin, VT; Wang, D; Williams, CT, 2019)	0.51
" They received a directly-observed 3-day standard treatment of DPQ and were followed up until day 63 for malaria infection and adverse events."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.51
"DPQ was highly efficacious and safe for the treatment of malaria in HIV-infected patients concurrently taking efavirenz- or nevirapine-based ART, despite known pharmacokinetic interactions between dihydroartemisinin-piperaquine and efavirenz- or nevirapine-based ART regimens."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.51
" Adverse events were assessed within four hours of drugs intake."	( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020)	0.56
"4%) of the study participants experienced mild and transient treatment-associated adverse events, post-treatment abdominal pain (27."	( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020)	0.56
" Both treatments were safe and well-tolerated."	( Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Assefa, DG; Bekele, D; Getachew, E; Joseph, M; Manyazewal, T; Tesfahunei, HA; Zeleke, ED, 2021)	0.62
" Adverse events (AE) were collected, with a special focus on cardiovascular safety by including electrocardiogram QT intervals evaluated after correction with either Bazett's (QTcB) or Fridericia's (QTcF) methods, at baseline and after treatment."	( Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries. Angheben, A; Bacchieri, A; Bardají, A; Behrens, RH; Bisoffi, Z; Bottieau, E; Bouchaud, O; Bourhis, Y; Calleri, G; Duparc, S; Hatz, C; Iannucelli, M; Jelinek, T; Martin, C; Mattera, GG; Mechain, M; Merlo Pich, E; Nothdurft, HD; Ramos, JM; Rapp, C; Rojo-Marcos, G; Salas-Coronas, J; Tommasini, S; Velasco, M; Vignier, N; Visser, LG, 2021)	0.62
" Reactive focal mass drug administration (rfMDA) may be safe and more effective."	( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial. Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021)	0.62
" No serious adverse events occurred."	( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial. Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021)	0.62
" Imatinib + SOC-treated participants exhibited no increase in number or severity of adverse events, a significantly accelerated decline in parasite density and pyrexia, and no DPC."	( Imatinib augments standard malaria combination therapy without added toxicity. Chien, HD; Kesely, KR; Low, PS; Noomuna, P; Pantaleo, A; Putt, KS; Tuan, TA; Turrini, FM, 2021)	0.62
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas."	( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021)	0.62
" Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday."	( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021)	0.62
" Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine is recommended for malaria prevention in HIV-uninfected women, but it is contraindicated in those HIV-infected on cotrimoxazole prophylaxis (CTXp) due to potential adverse effects."	( Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH Dimessa, LB; El Gaaloul, M; Esen, M; Garcia-Otero, L; González, R; Lagler, H; Lell, B; Menendez, C; Mischlinger, J; Mombo-Ngoma, G; Nhampossa, T; Piqueras, M; Pons-Duran, C; Ramharter, M; Sanz, S; Saute, F; Sevene, E; Tchouatieu, AM; Zoleko Manego, R, 2021)	0.62
" Secondary outcomes include prevalence of malaria-related maternal and infant outcomes and proportion of adverse perinatal outcomes."	( Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH Dimessa, LB; El Gaaloul, M; Esen, M; Garcia-Otero, L; González, R; Lagler, H; Lell, B; Menendez, C; Mischlinger, J; Mombo-Ngoma, G; Nhampossa, T; Piqueras, M; Pons-Duran, C; Ramharter, M; Sanz, S; Saute, F; Sevene, E; Tchouatieu, AM; Zoleko Manego, R, 2021)	0.62
" There were no reported serious adverse events associated with any of the regimens."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021)	0.62
"DP remains highly effective and safe for the treatment of uncomplicated malaria in Uganda."	( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021)	0.62
" No delay in parasite clearance nor severe adverse reaction was observed."	( Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia. Anggraeni, ND; Asih, PBS; Basri, HH; Bustos, MDG; Dewayanti, FK; Hutahaean, J; Kusumaningsih, M; Mulyani, PS; Robaha, M; Rozi, IE; Sariwati, E; Syafruddin, D; Wangsamuda, S; Zulfah, S, 2022)	0.72
" Adverse events over the first 28 days were reported in 27 (54%) of 50 patients treated with dihydroartemisinin-piperaquine alone, 29 (58%) of 50 patients treated with tafenoquine plus dihydroartemisinin-piperaquine, and 22 (44%) of 50 patients treated with primaquine plus dihydroartemisinin-piperaquine."	( Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023)	0.91
" Dihydroartemisinin-piperaquine and artesunate-amodiaquine were associated with a small number of mild adverse events, and there were no treatment-related serious adverse events or deaths."	( Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023)	0.91
"IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers."	( Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023)	0.91
" Artemisinin-based combination treatments are generally well tolerated, safe and effective; the most used being artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP)."	( Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of D'Alessandro, U; Dabira, ED; Diakite, H; Djimde, M; Dorlo, TP; Erhart, A; González, R; Kabore, B; Kayentao, K; Keita, M; Macuacua, S; Menendez, C; Mens, P; Muhindo, HM; Piqueras, M; Sagara, I; Schallig, H; Sevene, E; Tinto, H; Traore, M; Tshiongo, JK; Vala, A, 2023)	0.91
" RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration."	( Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023)	0.91

Excerpt	Reference	Relevance
"The relatively short half-life of ARM may be one of the factors responsible for the poor radical cure rate of falciparum malaria with regimens employing daily dosing."	( Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Mansor, SM; Mordi, MN; Navaratnam, V; Wernsdorfer, WH, 1997)	0.3
" Pharmacokinetic parameters were calculated by non-compartmental methods."	( A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Kim, NV; Mai, TX; Powell, SM; Thien, HV; Thu, LT; Tien, NP, 1998)	0.3
" bolus, ARTS had a peak concentration of 29."	( A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Kim, NV; Mai, TX; Powell, SM; Thien, HV; Thu, LT; Tien, NP, 1998)	0.3
" The resulting pharmacokinetic parameter estimates were substantially different not only between drugs but also between routes of administration for the same drug."	( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998)	0.3
" Patients with ARF had significantly higher Cmax [2."	( Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure. Harinasuta, T; Karbwang, J; Na-Bangchang, K; Rimchala, W; Sukontason, K; Tin, T, 1998)	0.3
"A single cross-over, comparative pharmacokinetic study of oral and rectal formulations of 200 mg artesunic acid in 12 healthy Malaysian volunteers is reported."	( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998)	0.3
"Comparison of pharmacokinetic parameters of artesunic acid after oral and rectal administration showed statistically significant differences in t(max) and AUC, with no changes for Cmax and t1/2."	( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998)	0.3
"There appear to be pharmacokinetic differences between oral and rectal modes of administration."	( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998)	0.3
"Pharmacokinetic and pharmacodynamic interactions between dihydroartemisinin and mefloquine were investigated in 10 healthy Thai males."	( Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin. Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P; Ubalee, R, 1999)	0.3
" The pharmacokinetic parameters of mefloquine were estimated using non-compartmental and compartmental analysis."	( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000)	0.31
" Mefloquine from the three formulations showed significantly different pharmacokinetic and bioavailability metrics."	( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000)	0.31
" The pharmacokinetic curves of artemether and its metabolites dihydroartemisinin and furano acetate of artemether were determined and the results showed that the half-life of artemether under the conditions simulated the pH of plasma or small intestine was more than 150 min and that of stomach acid was 74."	( [Pharmacokinetic studies on artemether under conditions simulated in vivo]. Chen, YG; Yu, BY, 2002)	0.31
"4 (range 5-108) months were recruited into the study and data from 90 of these children (30 with respiratory distress and 60 with no respiratory distress) were used in the population pharmacokinetic analysis."	( Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Aarons, L; Edwards, G; Kokwaro, GO; Majid, O; Marsh, K; Mithwani, S; Mohamed, S; Muchohi, S; Watkins, W, 2004)	0.32
" Cmax values of 63."	( Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria. Chalearmrult, K; Krudsood, S; Li, Q; Looareesuwan, S; Lugt, CB; Milhous, WK; Vannaphan, S; Wilairatana, P, 2004)	0.32
" Significant changes in the pharmacokinetic parameters of both mefloquine and dihydroartemisinin were observed in patients with malaria compared with healthy subjects reported in a paralleled study."	( Pharmacokinetics of the four combination regimens of dihydroartemisinin/mefloquine in acute uncomplicated falciparum malaria. Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P, 2005)	0.33
" The beta-isomer of arteether was characterized by a longer elimination half-life and a relatively larger volume of distribution than the alpha-isomer, suggesting that beta-arteether may be responsible for the prolonged in vivo schizontocidal activity."	( Pharmacokinetics of the diastereomers of arteether, a potent antimalarial drug, in rats. Gupta, RC; Madhusudanan, KP; Sabarinath, S, 2005)	0.33
"To determine the pharmacokinetic properties of dihydroartemisinin (DHA) following oral artesunate treatment in women with recrudescent multi-drug resistant falciparum malaria, in the second and third trimesters of pregnancy."	( Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Cho, T; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; Ward, SA; White, NJ, 2006)	0.33
" Conventional non-compartmental modelling and a population one-compartment pharmacokinetic model were applied to the data."	( Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Cho, T; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; Ward, SA; White, NJ, 2006)	0.33
"To investigate the pharmacokinetic properties of piperaquine after repeated oral administration of the antimalarial combination CV8 in healthy subjects."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	0.33
" Population pharmacokinetic parameter estimates were obtained by nonlinear mixed effects modeling of the observed data using NONMEM."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	0.33
" Piperaquine pharmacokinetics were characterized by a large volume of distribution and a terminal half-life of several days."	( Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Ashton, M; Friberg Hietala, S; Hai, TN; Röshammar, D; Van Huong, N, 2006)	0.33
"To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria."	( The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006)	0.33
" Serial blood samples were taken over a 7-day period, and pharmacokinetic parameters were estimated."	( The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006)	0.33
" The pharmacokinetic properties of DHA were determined using nonlinear mixed-effects modelling."	( Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. Agbenyega, T; Barnes, KI; Di Perri, G; Folb, P; Gomes, M; Krishna, S; Krudsood, S; Looareesuwan, S; Mansor, S; McIlleron, H; Miller, R; Molyneux, M; Mwenechanya, J; Navaratnam, V; Nosten, F; Olliaro, P; Pang, L; Ribeiro, I; Simpson, JA; Tembo, M; van Vugt, M; Ward, S; Weerasuriya, K; White, NJ; Win, K, 2006)	0.33
"The pharmacokinetic properties of DHA were affected only by gender and body weight."	( Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. Agbenyega, T; Barnes, KI; Di Perri, G; Folb, P; Gomes, M; Krishna, S; Krudsood, S; Looareesuwan, S; Mansor, S; McIlleron, H; Miller, R; Molyneux, M; Mwenechanya, J; Navaratnam, V; Nosten, F; Olliaro, P; Pang, L; Ribeiro, I; Simpson, JA; Tembo, M; van Vugt, M; Ward, S; Weerasuriya, K; White, NJ; Win, K, 2006)	0.33
" It was concluded that since no pharmacokinetic drug interaction was observed, MQ dose given 24 hours after an initial dose of DHA is a preferable combination treatment regimen with regard to patient compliance."	( Pharmacokinetics of mefloquine with dihydroartemisinin as 2-day regimens in patients with uncomplicated falciparum malaria. Hung, le N; Hung, NC; Na-Bangchang, K; Thuy, le TD, 2007)	0.34
"Antimalarial treatment strategies based on in vitro studies are limited by the paucity of pharmacodynamic information for dosage regimen design."	( Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Barrett, PH; Batty, KT; Davis, TM; Gibbons, PL; Ilett, KF, 2007)	0.34
" However, there is a paucity of detailed preclinical and pharmacokinetic data to link PQ serum concentrations and toxicity or efficacy."	( Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Andrzejewski, C; Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M, 2008)	0.35
" The mean pharmacokinetic parameters of DHA in a single dose were: t(1/2(beta))=1."	( Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers. Hong, X; Huang, TL; Huang, XT; Liu, CH; Mi, SQ; Ou, WP; Wang, NS; Ye, SM, 2008)	0.35
"The aim was to study the pharmacokinetic profile of artesunate and its metabolite dihydroartemisinin (DHA) in a pig model."	( Pharmacokinetics of artesunate in the domestic pig. Aglioni, C; Bressolle, FM; Mosnier, J; Parzy, D; Sinou, V; Taudon, N, 2008)	0.35
"The pharmacokinetic properties of artesunate and DHA in pigs were similar to those reported in humans, suggesting that the swine model is suitable for determining the preclinical pharmacokinetics of artemisinin derivatives."	( Pharmacokinetics of artesunate in the domestic pig. Aglioni, C; Bressolle, FM; Mosnier, J; Parzy, D; Sinou, V; Taudon, N, 2008)	0.35
" Reduced half-life (T(1/2z)) and lower area under concentration curve (AUC(infinity)) values were observed on the final day of treatment in comparison to those obtained on the first day."	( Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. Le Thi, DT; Le, NH; Na-Bangchang, K; Nguyen, CH; Phan Thi, D, 2008)	0.35
" The aim of this study was to determine the influence of a standard Vietnamese meal on the single-dose pharmacokinetics of piperaquine when administered in combination with dihydroartemisinin, and to gain extended data on the terminal half-life of piperaquine in healthy Vietnamese volunteers."	( The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Ashton, M; Hai, TN; Hietala, SF; Van Huong, N, 2008)	0.35
"The pharmacokinetic (PK) parameters of artesunate, recently discovered to possess promising trematocidal activity, and its main metabolite dihydroartemisinin (DHA) were determined in rats infected with hepatic and biliary stages of Fasciola hepatica and compared with uninfected rats after single intragastric and intravenous (iv) doses."	( Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica. Decosterd, L; Gruyer, MS; Keiser, J; Mercier, T; Perrottet, N; Zanolari, B, 2009)	0.35
" Blood samples for pharmacokinetic analysis were collected up to 24 h post-first dose."	( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009)	0.35
"The pharmacokinetic analysis included 115 patients."	( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009)	0.35
" Nonlinear mixed-effect modelling was used to obtain the pharmacokinetic and variability (inter-individual and residual variability) parameter estimates."	( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009)	0.35
"A novel parent-metabolite pharmacokinetic model consisting of a dosing compartment, a central compartment for AS, a central compartment and a peripheral compartment for DHA was developed."	( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009)	0.35
"A novel simultaneous parent-metabolite pharmacokinetic model with good predictive power was developed to study the population pharmacokinetics of AS and DHA in healthy subjects following single- and multiple-dosing of AS with or without the presence of food."	( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009)	0.35
" The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation)."	( Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. Alegre, SS; Benakis, A; Bertaux, L; Lwango, R; Malaika, LT; Parzy, D; Sinou, V; Sugnaux, F; Taudon, N, )	0.13
"The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani subjects are comparable to healthy subjects and patients from other populations."	( Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Ali, S; Lindegardh, N; Najmi, MH; Tarning, J, 2010)	0.36
" Pharmacokinetic and safety data supporting the use of artemisinin derivatives in pregnancy are urgently needed."	( Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Atibu, J; Bose, C; Capparelli, EV; Douoguih, M; Fleckenstein, L; Hemingway-Foday, J; Koch, MA; Lokomba, V; Meshnick, SR; Onyamboko, MA; Ryder, RW; Tshefu, AK; Wesche, D; Wright, LL, 2011)	0.37
" Non-compartmental pharmacokinetic analysis was performed using standard methods."	( Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Atibu, J; Bose, C; Capparelli, EV; Douoguih, M; Fleckenstein, L; Hemingway-Foday, J; Koch, MA; Lokomba, V; Meshnick, SR; Onyamboko, MA; Ryder, RW; Tshefu, AK; Wesche, D; Wright, LL, 2011)	0.37
" Estimates for pharmacokinetic and variability parameters were obtained through nonlinear mixed effects modelling."	( Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Atibu, J; Bose, C; Capparelli, E; Douoguih, M; Fleckenstein, L; Hemingway-Foday, J; Koch, MA; Lokomba, V; Meshnick, S; Morris, CA; Onyamboko, MA; Ryder, RW; Tshefu, AK; Wesche, D; Wright, L, 2011)	0.37
"In this analysis, pharmacokinetic modelling suggests that pregnant women have accelerated DHA clearance compared to non-pregnant women receiving orally administered AS."	( Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Atibu, J; Bose, C; Capparelli, E; Douoguih, M; Fleckenstein, L; Hemingway-Foday, J; Koch, MA; Lokomba, V; Meshnick, S; Morris, CA; Onyamboko, MA; Ryder, RW; Tshefu, AK; Wesche, D; Wright, L, 2011)	0.37
" Pharmacokinetic data for CQ in animal models are limited; thus, we conducted a three-part investigation, comprising (i) pharmacodynamic studies of CQ and CQ plus dihydroartemisinin (DHA) in Plasmodium berghei-infected mice, (ii) pharmacokinetic studies of CQ in healthy and malaria-infected mice, and (iii) interspecies allometric scaling for CQ from 6 animal and 12 human studies."	( Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M; Stoney, JR, 2011)	0.37
" Intravenous AS is associated with high initial AS concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes."	( Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Jung, D; Morris, CA; Shin, CS, 2011)	0.37
"0057), and the terminal elimination half-life was significantly shorter (17."	( Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Laochan, N; Lindegardh, N; McGready, R; Mu, O; Nosten, F; Phyo, AP; Rijken, MJ; Singhasivanon, P; Tarning, J; Than, HH; White, N; Win, AK, 2011)	0.37
" The pharmacokinetic properties of antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations and a consequently higher risk of treatment failure."	( Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Day, NP; Hanpithakpong, W; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; White, NJ, 2012)	0.38
" The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso."	( Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Day, NP; Hanpithakpong, W; Jongrak, N; Lindegardh, N; Nosten, F; Ouedraogo, JB; Parikh, S; Rosenthal, PJ; Rouamba, N; Somé, FA; Tarning, J; White, NJ; Zongo, I, 2012)	0.38
" No significant dose-effect or concentration-effect relationships between pharmacokinetic (PK) and parasite clearance parameters were observed, though baseline parasitemia was modestly correlated with increased parasite clearance times."	( Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Bethell, D; Chanthap, L; Fukuda, M; Khemawoot, P; Lin, J; Noedl, H; Ringwald, P; Rutvisuttinunt, W; Saunders, D; Se, Y; Siripokasupkul, R; Smith, B; Socheat, D; Sriwichai, S; Teja-Isavadharm, P; Timmermans, A; Tyner, S; Vanachayangkul, P, 2012)	0.38
" Pregnancy has been reported to alter the pharmacokinetic properties of many anti-malarial drugs."	( Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Day, NP; Dhorda, M; Guerin, PJ; Kloprogge, F; Lindegardh, N; Muwanga, S; Nosten, F; Nuengchamnong, N; Piola, P; Tarning, J; Turyakira, E; White, NJ, 2012)	0.38
" A simultaneous drug-metabolite population pharmacokinetic model for artemether and dihydroartemisinin was developed taking into account different disposition, absorption, error and covariate models."	( Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Day, NP; Dhorda, M; Guerin, PJ; Kloprogge, F; Lindegardh, N; Muwanga, S; Nosten, F; Nuengchamnong, N; Piola, P; Tarning, J; Turyakira, E; White, NJ, 2012)	0.38
"002) with EFV, but the LR half-life was unchanged."	( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012)	0.38
" The sex-specific effect on the pharmacokinetic profiles of DHA and its metabolites was studied."	( An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat. Du, F; Li, X; Xing, J; Zhu, F, 2012)	0.38
" The pharmacokinetic properties of many anti-malarials are also altered during pregnancy, often resulting in a decreased drug exposure."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.38
" A statistically significant decrease in estimated terminal piperaquine half-life in pregnant compared with non-pregnant women was found, but there were no differences in post-hoc estimates of total piperaquine exposure."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.38
"The population pharmacokinetic properties of piperaquine were well described by a three-compartment disposition model in pregnant and non-pregnant women with uncomplicated malaria."	( A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Adam, I; Ashton, M; Day, NP; Hanpithakpong, W; Hoglund, RM; Lindegardh, N; Nosten, F; Tarning, J; White, NJ, 2012)	0.38
" A population pharmacokinetic study of ARS and dihydroartemisinin (DHA) was conducted from sparse sampling in 70 Tanzanian children of ages 6 months to 11 years."	( Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Day, NP; Dondorp, AM; Gesase, S; Hendriksen, IC; Kent, A; Lemnge, MM; Lindegardh, N; Mtove, G; Reyburn, H; Tarning, J; von Seidlein, L; White, NJ, 2013)	0.39
"Pregnancy alters the pharmacokinetic properties of many drugs used in the treatment of malaria, usually resulting in lower drug exposures."	( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013)	0.39
"Simultaneous modelling of dense and sparse pharmacokinetic data is possible with a population approach."	( Statistical power calculations for mixed pharmacokinetic study designs using a population approach. Day, NP; Kloprogge, F; Simpson, JA; Tarning, J; White, NJ, 2014)	0.4
" The objective of this study is to show the pharmacokinetic (PK) profile of intravenous artesunate (AS), which was manufactured under good manufacturing practice (GMP) conditions, in adults with uncomplicated falciparum malaria in Kenya."	( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014)	0.4
" Pharmacokinetic data were analysed with a compartmental analysis for AS and DHA."	( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014)	0.4
" The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL."	( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014)	0.4
" Given the much longer half-life of DHA compared to the short half-life of AS, DHA also plays a significant role in treatment of severe malaria."	( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014)	0.4
" Compartmental pharmacokinetic models for PQ and DHA were developed using a population-based approach."	( Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Batty, KT; Benjamin, JM; Davis, TM; Ginny, E; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P, 2014)	0.4
" A combined drug-metabolite population pharmacokinetic model was developed to describe the plasma pharmacokinetics of ARS and DHA in plasma."	( Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Äbelö, A; Ashton, M; Blank, A; Ericsson, T; von Hagens, C, 2014)	0.4
" Pharmacokinetic assessment was done with a noncompartmental approach."	( Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Ashley, EA; Chotsiri, P; Day, NP; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Lee, SJ; Panapipat, S; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2014)	0.4
" A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs."	( Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015)	0.42
" The polymorphic effects of UGT1A9 (I399C>T) and UGT2B7*2 (802C>T), the major enzymes involved in the metabolism of DHA, on the pharmacokinetic profiles of DHA and its metabolite was also studied."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.4
" No polymorphic effect was found for UGT1A9 (I399C>T) and UGT2B7*2 (802C>T) on the pharmacokinetic profiles of DHA and its metabolite DHA-Glu."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.4
" Malaria and pregnancy had no effect on the pharmacokinetic properties of artesunate or dihydroartemisinin after intravenous artesunate administration."	( Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Day, NP; Hanpithakpon, W; Hlaing, N; Kloprogge, F; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; Than, HH; White, NJ; Zin, NT, 2015)	0.42
"The population pharmacokinetic analysis demonstrated opposite effects of malaria and pregnancy on the bioavailability of orally administered artesunate."	( Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Day, NP; Hanpithakpon, W; Hlaing, N; Kloprogge, F; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; Than, HH; White, NJ; Zin, NT, 2015)	0.42
" Compartmental pharmacokinetic models were developed using a population-based approach."	( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015)	0.42
"Piperaquine-dihydroartemisinin combination therapy has established efficacy for the treatment of malaria; however, a more comprehensive understanding of the pharmacokinetic properties and factors contributing to inter- and intra-individual variability is critical to optimize clinical use."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	0.42
" Blood samples were collected for analysis of plasma piperaquine and dihydroartemisinin concentrations, which were utilized for calculation of pharmacokinetic parameters, using a standard model-independent approach."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	0.42
" The observation of a shorter terminal half-life for lumefantrine may have contributed to a higher frequency of reinfection or a shorter posttreatment prophylactic period in pregnant women than in nonpregnant adults."	( Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Achan, J; Aweeka, F; Huang, L; Kajubi, R; Kiconco, S; Mwebaza, N; Mwima, MW; Nguyen, VK; Nyunt, MM; Parikh, S; Ssebuliba, J, 2015)	0.42
"Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21% of patients."	( Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Ashley, EA; Aung, SS; Day, NP; Dhorda, M; Dondorp, AM; Hlaing, TM; Imwong, M; Jeeyapant, A; Promnarate, C; Smithuis, FM; Thein, M; Tun, KM; White, NJ; Woodrow, CJ; Yuentrakul, P, 2016)	0.43
" The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods."	( Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A, 2016)	0.43
" A population pharmacokinetic model was developed to compare exposure-response relationships between the 2DP and 3DP regimens while accounting for differences in regimen and sample collection times between studies."	( Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia. Buathong, N; Cantilena, L; Chann, S; Haigney, M; Ittiverakul, M; Kodchakorn, C; Kuntawunginn, W; Lanteri, C; Lon, C; Manning, J; Milner, E; Pann, ST; Prom, S; Saunders, D; So, M; Sok, S; Spring, M; Sriwichai, S; Ta-Aksorn, W; Vanachayangkul, P; Wojnarski, M; Youdaline, T, 2017)	0.46
"The aims of the present study were to evaluate the pharmacokinetic properties of dihydroartemisinin (DHA) and piperaquine, potential drug-drug interactions with concomitant primaquine treatment, and piperaquine effects on the electrocardiogram in healthy volunteers."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.46
"The population pharmacokinetic properties of DHA and piperaquine were assessed in 16 healthy Thai adults using an open-label, randomized, crossover study."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.46
" Concomitant treatment with primaquine did not affect the pharmacokinetic properties of DHA or piperaquine."	( Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Blessborn, D; Chotsiri, P; Day, NPJ; Hanboonkunupakarn, B; Hoglund, RM; Jittamala, P; Pukrittayakamee, S; Tarning, J; Wattanakul, T; White, NJ, 2017)	0.46
"Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
"Population pharmacokinetic models characterizing the enantiospecific properties of primaquine were developed successfully."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
" The pharmacokinetic differences among blood cells and plasma still remain unclear."	( Comparison of in vitro/in vivo blood distribution and pharmacokinetics of artemisinin, artemether and dihydroartemisinin in rats. Dai, R; Dai, T; Guo, Z; Jiang, W; Xie, Y, 2019)	0.51
" All studies on ART and DHA pharmacokinetic post-administration of artesunate in human patients or volunteers were included."	( Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. Bienvenu, AL; Bonnot, G; Kouakou, YI; Lavoignat, A; Leboucher, G; Picot, S; Tod, M, 2019)	0.51
" However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for in vivo resistance, patient clearance half-life post-artemisinin treatment."	( The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput. Anderson, TJC; Button-Simons, KA; Cassady, Z; Checkley, LA; Davis, SZ; Ferdig, MT; Foster, GJ; McDew-White, M; Nosten, FH; Shoue, DA; Sievert, MAC; Singh, PP; Vendrely, KM, 2020)	0.56
" Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample."	( The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput. Anderson, TJC; Button-Simons, KA; Cassady, Z; Checkley, LA; Davis, SZ; Ferdig, MT; Foster, GJ; McDew-White, M; Nosten, FH; Shoue, DA; Sievert, MAC; Singh, PP; Vendrely, KM, 2020)	0.56
" To optimally apply these drugs, information about their tissue-specific disposition is required, and one approach to predict these pharmacokinetic characteristics is physiologically based pharmacokinetic (PBPK) modeling."	( Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling. Arey, R; Reisfeld, B, 2021)	0.62
" On this basis, the chemical components of XECQ were targeted and enriched by network pharmacology, to screen the main pharmacodynamic substances of XECQ in the treatment of acute upper respiratory tract infection in children and discuss the mechanism of action."	( [Pharmacodynamic substances and mechanism of action of Xiaoer Chiqiao Qingre Granules in treatment of acute upper respiratory tract infection in children]. Feng, L; Jia, XB; Liu, J; Lu, GZ; Yang, YJ; Zhao, J; Zhu, MM; Zhu, XJ, 2022)	0.72

Excerpt	Reference	Relevance
"To observe the therapeutic efficacy of dihydroartemisinin combined with naphthoquine phosphate in patients with falciparum malaria."	( [Therapeutic effect of dihydroartemisinin combined with naphthoquine phosphate in patients with falciparum malaria]. Lin, SG; Meng, F; Pang, XJ; Shen, H; Wang, SQ; Wen, Y; Zeng, LH; Zhu, QX; Zhuo, KR, 2002)	0.31
"Patients with Plasmodium falciparum were selected as the subjects, treated with a single dose of dihydroarteminisinin 160 mg combined with naphthoquine phosphate 400 mg (for adults) and followed up in preselective time by blood and temperature examination for 28 days after drug administration."	( [Therapeutic effect of dihydroartemisinin combined with naphthoquine phosphate in patients with falciparum malaria]. Lin, SG; Meng, F; Pang, XJ; Shen, H; Wang, SQ; Wen, Y; Zeng, LH; Zhu, QX; Zhuo, KR, 2002)	0.31
" This study was conducted to evaluate the antimalarial potential of clindamycin in combination with dihydroartemisinin in continuously cultured and in freshly isolated Plasmodium falciparum parasites, measuring the inhibition of Plasmodium falciparum histidine-rich protein II synthesis."	( In vitro activity and interaction of clindamycin combined with dihydroartemisinin against Plasmodium falciparum. Graninger, W; Kremsner, PG; Noedl, H; Ramharter, M; Wernsdorfer, WH; Winkler, H; Winkler, S, 2003)	0.32
" Competitive uptake of radiolabeled chloroquine and dihydroartemisinin in combination with other antimalarials was observed."	( Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains. Adagu, IS; Fivelman, QL; Warhurst, DC, 2007)	0.34
" This study also demonstrated the effectiveness of high-resolution mass spectrometry in combination with an online H/D exchange LC/HR-MS(n) technique in rapid identification of drug metabolites."	( Metabolite identification of artemether by data-dependent accurate mass spectrometric analysis using an LTQ-Orbitrap hybrid mass spectrometer in combination with the online hydrogen/deuterium exchange technique. Du, F; Liu, T; Xing, J; Zhu, F, 2011)	0.37
"A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronaridine/artesunate (PA) combination antimalarial and ritonavir."	( Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Jung, D; Lopez-Lazaro, L; Methaneethorn, J; Morris, CA; Pokorny, R; Shin, CS, 2012)	0.38
"A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure."	( A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. Chavez, I; Chokejindachai, W; Dondorp, AM; Imwong, M; Pasaribu, AP; Pasaribu, S; Sirivichayakul, C; Tanomsing, N; Tjitra, E; White, NJ, 2013)	0.39
"Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP) is the first-line therapy for management of uncomplicated Plasmodium falciparum malaria in Sudan."	( Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers. Awad, AI; Elamin, SB; Matar, KM, 2014)	0.4
" Therefore, a more thorough assessment of their potential clinical use through a rodent model and an in vitro evaluation of their combination with artemisinin was undertaken."	( Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model. Agnamey, P; Degrouas, C; Jonet, A; Mullié, C; Pascual, A; Sonnet, P; Taudon, N, 2014)	0.4
" falciparum clones with varying resistance profiles and regional origins was performed for the (S)-pentyl and (S)-heptyl substituted quinoline derivatives, followed by an in vitro assessment of their combination with dihydroartemisinin (DHA) on the 3D7 clone and an in vivo assay in a mouse model infected with Plasmodium berghei."	( Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model. Agnamey, P; Degrouas, C; Jonet, A; Mullié, C; Pascual, A; Sonnet, P; Taudon, N, 2014)	0.4
" The in vitro combination with DHA yielded an additive or synergic effect for both that was as good as that of the DHA/MQ combination."	( Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model. Agnamey, P; Degrouas, C; Jonet, A; Mullié, C; Pascual, A; Sonnet, P; Taudon, N, 2014)	0.4
"Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
"Enantiomeric pharmacokinetics were evaluated in 49 healthy adult volunteers enrolled in three randomized cross-over studies in which a single dose of primaquine was given alone and then, after a suitable washout period, in combination with chloroquine, dihydroartemisinin/piperaquine or pyronaridine/artesunate."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
" No drug-drug interaction effects were seen on the pharmacokinetics of either carboxyprimaquine enantiomer."	( Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)	0.48
" Furthermore, doxycycline has anti-malarial properties and is already recommended as prophylaxis for travellers and for treatment of falciparum malaria in combination with other anti-malarial drugs."	( Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa? Boxberger, M; Gaillard, T; Madamet, M; Pradines, B, 2018)	0.48
" Thus, we are in dire need of alternate chemotherapeutic agents which in combination with artemisinin (or its analogues) are efficacious against chloroquine-resistant strains."	( In vitro synergistic interaction of potent 4-aminoquinolines in combination with dihydroartemisinin against chloroquine-resistant Plasmodium falciparum. Agarwal, D; Awasthi, SK; Gupta, RD; Singh, S, 2019)	0.51
" Although the clinical importance remains unclear to date, clinicians should be aware of potential drug-drug interactions and monitor patients on ACT closely."	( Drug-Drug Interactions of Artemisinin-Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature. Grundmann, O; Hernandez Maldonado, J, 2022)	0.72
" We aimed to establish the efficacy and safety of three single low doses of tafenoquine in combination with dihydroartemisinin-piperaquine for reducing gametocyte density and transmission to mosquitoes."	( Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF, 2022)	0.72
" This study evaluated the efficacy of different dosages of aqueous extract of Strychnos ligustrina combined with dihydroartemisinin and piperaquine phosphate (DHP) against murine Plasmodium berghei infection."	( Antimalarial Efficacy of Aqueous Extract of Strychnos ligustrina and Its Combination with Dihydroartemisinin and Piperaquine Phosphate (DHP) against Plasmodium berghei Infection. Cahyaningsih, U; Maring, AJ; Nugraha, AB; Sa'diah, S; Sari, RK; Syafii, W, 2022)	0.72

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Tetrazole, a bioisostere of the carboxylic acid group, can replace the carboxyl group in drugs to increase the lipophilicity, bioavailability and reduce side effects."	( Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents. Chang, L; Ding, C; Feng, LS; Gao, C; Wu, X; Xu, Z; Yan, XF; Zhao, F, 2019)	0.51
" It would appear that the bioavailability of DHQHS tablets is much higher than that of QHS when given orally to the dog."	( [The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. Song, ZY; Zhao, KC, 1990)	0.28
" We conclude that the bioavailability of intramuscular AM in children with severe malaria may be highly variable, particularly in the presence of respiratory distress, and may be associated with an inadequate therapeutic response."	( The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Crawley, J; English, M; Lowe, B; Marsh, K; Mberu, E; Muhia, D; Murphy, SA; Newton, CR; Waruiru, C; Watkins, WM; Winstanley, P, )	0.13
"The pharmacokinetics and bioavailability of dihydroartemisinin (DQHS), artemether (AM), arteether (AE), artesunic acid (AS) and artelinic acid (AL) have been investigated in rats after single intravenous, intramuscular and intragastric doses of 10 mg kg(-1)."	( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998)	0.3
" Pharmacokinetics of dihydroartemisinin and mefloquine when given concurrently were similar, except for the absorption rate of mefloquine which was faster in the presence of dihydroartemisinin."	( Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin. Karbwang, J; Na-Bangchang, K; Thanavibul, A; Tippawangkosol, P; Ubalee, R, 1999)	0.3
" The aim of this study was to evaluate the effect of grapefruit juice on the decreasing bioavailability over time of artemether."	( The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Gupta, V; van Agtmael, MA; van Boxtel, CJ; van der Graaf, CA, 1999)	0.3
"Grapefruit juice significantly increased the oral bioavailability of artemether but did not prevent the time-dependent reduction in bioavailability."	( The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Gupta, V; van Agtmael, MA; van Boxtel, CJ; van der Graaf, CA, 1999)	0.3
" Mefloquine from the three formulations showed significantly different pharmacokinetic and bioavailability metrics."	( Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH, 2000)	0.31
"To obtain comprehensive bioavailability data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following their separate oral administration to Vietnamese volunteers and to patients with acute, uncomplicated falciparum malaria."	( Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Phuöng, HL; Phuong, VD; Powell, SM; Thien, HV; Thu, LT, 2001)	0.31
" Pharmacokinetic descriptors were obtained from noncompartmental analysis and bioavailability was calculated from AUC data."	( Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Phuöng, HL; Phuong, VD; Powell, SM; Thien, HV; Thu, LT, 2001)	0.31
"In Group 1 (volunteers), the mean (95% CI) absolute bioavailability of oral ARTS was 80% (62,98%), while in Group 2 (volunteers), the bioavailability of oral DHA was 45% (34,56%)."	( Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Phuöng, HL; Phuong, VD; Powell, SM; Thien, HV; Thu, LT, 2001)	0.31
"The study shows that the absolute bioavailability of DHA was significantly lower than that for ARTS in healthy volunteers."	( Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Batty, KT; Binh, TQ; Davis, TM; Hung, NC; Ilett, KF; Phuöng, HL; Phuong, VD; Powell, SM; Thien, HV; Thu, LT, 2001)	0.31
"34 hr, and the bioavailability over 12 hr (area under the curve [AUC](0-12)) was 253+/-185 nmol hr/L."	( Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Brewer, TG; Eamsila, C; Jongsakul, K; Keeratithakul, G; Kyle, DE; Li, Q; Luesutthiviboon, L; Sirisopana, N; Teja-Isavadharm, P; Watt, G, 2001)	0.31
" The mean antimalarial activity in terms of the bioavailability of DHA relative to that of artesunate did not differ significantly from 1, suggesting that DHA can be formulated to be an acceptable oral alternative to artesunate."	( Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Looareesuwan, S; Newton, PN; Nosten, F; Rasameesoroj, M; Ruangveerayuth, R; Siriyanonda, D; Slight, T; Suputtamongkol, Y; Teerapong, P; Teja-Isavadharm, P; van Vugt, M; White, NJ, 2002)	0.31
"The aim of this study was to evaluate the bioavailability of artesunate (ARTS) and dihydroartemisinin (DHA)."	( Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Batty, KT; Davis, TM; Iletr, KE; Martin, J; Powell, SM, 2002)	0.31
" The mean common volumes of distribution for ARTS and DHA relative to bioavailability were 42."	( Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Alpers, MP; Barrett, PH; Bockarie, M; Davis, TM; Dufall, K; Ilett, KF; Karunajeewa, HA; Kemiki, A; Vicini, P, 2004)	0.32
" Patients with the lowest area under the DHA concentration curve did not have slower parasite clearance, suggesting that rectal artesunate is well absorbed in most patients with moderately severe malaria."	( Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. Agbenyega, T; Barnes, KI; Di Perri, G; Folb, P; Gomes, M; Krishna, S; Krudsood, S; Looareesuwan, S; Mansor, S; McIlleron, H; Miller, R; Molyneux, M; Mwenechanya, J; Navaratnam, V; Nosten, F; Olliaro, P; Pang, L; Ribeiro, I; Simpson, JA; Tembo, M; van Vugt, M; Ward, S; Weerasuriya, K; White, NJ; Win, K, 2006)	0.33
" This thermolability coupled with the poor physicochemical properties and relative oral bioavailability of DHA suggests that it is inferior to artesunate in application as an antimalarial drug."	( Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. Cartwright, A; Chan, HW; Gomes, MF; Haynes, RK; Lung, CM; Ng, NC; Shek, LY; Williams, ID; Wong, HN, 2007)	0.34
" We summarized the data under the following themes: content and dissolution; relative bioavailability of antimalarial products; antimalarial stability and shelf life; general tests on pharmaceutical dosage forms; and the presence of degradation or unidentifiable impurities in formulations."	( Antimalarial drug quality in Africa. Amin, AA; Kokwaro, GO, 2007)	0.34
" The literature was varied in the quality and breadth of data presented, with most bioavailability studies poorly designed and executed."	( Antimalarial drug quality in Africa. Amin, AA; Kokwaro, GO, 2007)	0.34
"79 L/kg); the bioavailability was 100%."	( Pharmacokinetics of artesunate in the domestic pig. Aglioni, C; Bressolle, FM; Mosnier, J; Parzy, D; Sinou, V; Taudon, N, 2008)	0.35
" The method is sensitive, selective, accurate, reproducible and suited particularly for pharmacokinetic study of AS-AQ drug combination and can also be used to compare the bioavailability of different formulations, including a fixed-dose AS-AQ co-formulation."	( Validation of high performance liquid chromatography-electrochemical detection methods with simultaneous extraction procedure for the determination of artesunate, dihydroartemisinin, amodiaquine and desethylamodiaquine in human plasma for application in c Lai, CS; Mansor, SM; Muniandy, A; Nair, NK; Navaratnam, V; Olliaro, PL, 2009)	0.35
" In addition, the oral bioavailability of piperaquine improves when given with a high-fat meal, though this does not necessarily translate into a higher efficacy."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.35
" During early development of this new formulation, two studies were performed in healthy subjects, one to evaluate the palatability of three flavours of A-L, and a second one to compare the bioavailability of active principles between the dispersible tablet and the tablet (administered crushed and intact)."	( Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Abdulla, S; Amuri, B; Fitoussi, S; Kabanywanyi, AM; Kaiser, G; Lefèvre, G; Nuortti, M; Pascoe, S; Reynolds, C; Séchaud, R; Ubben, D; Yeh, CM, 2010)	0.36
" The objectives were to compare the bioavailability of artemether, dihydroartemisinin (DHA) and lumefantrine between the dispersible tablet and the tablet administered crushed (primary objective) and intact (secondary objective)."	( Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Abdulla, S; Amuri, B; Fitoussi, S; Kabanywanyi, AM; Kaiser, G; Lefèvre, G; Nuortti, M; Pascoe, S; Reynolds, C; Séchaud, R; Ubben, D; Yeh, CM, 2010)	0.36
"The aim of the present study was to compare the pharmacokinetic properties, bioavailability and tolerability of artesunate (AS) and amodiaquine (AQ) administered as a fixed-dose combination (Amonate FDC tablets; Dafra Pharma, Turnhout, Belgium) or as a non-fixed dose combination of separate AS tablets (Arsuamoon; Guilin Pharmaceutical Co, Shanghai, China) and AQ tablets (Flavoquine; Sanofi-Aventis, Paris, France)."	( Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers. Fortin, A; Jansen, FH; Verbeeck, RK, 2011)	0.37
"Dihydroartemisinin (DHA) is a poorly water-soluble drug that displays low bioavailability after oral administration."	( Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes. Ansari, MT; Batty, KT; Iqbal, I; Sunderland, VB, 2011)	0.37
" The lipophilic characteristic of piperaquine suggests that administration together with fat will increase the oral bioavailability of the drug, and this has been reported for healthy volunteers."	( A small amount of fat does not affect piperaquine exposure in patients with malaria. Annerberg, A; Ashley, E; Day, NP; Khrutsawadchai, S; Lindegardh, N; Lwin, KM; Nosten, F; Singhasivanon, P; Tarning, J; White, NJ, 2011)	0.37
" Similarly high bioavailability of DHA (> 80%) is associated with oral administration."	( Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Jung, D; Morris, CA; Shin, CS, 2011)	0.37
" The corresponding median absolute oral bioavailability (F%) was 21."	( Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Hanpithakpon, W; Hlaing, N; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Singhasivanon, P; Tarning, J; Than, HH; White, NJ; Zin, NT, 2012)	0.38
" Piperaquine was best described by a three-compartment disposition model with a 45% higher elimination clearance and a 47% increase in relative bioavailability in pregnant women compared with nonpregnant women."	( Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Day, NP; Hanpithakpong, W; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; White, NJ, 2012)	0.38
" This study examined increasing DHA bioavailability by encapsulating DHA within gelatin (GEL) or hyaluronan (HA) nanoparticles via an electrostatic field system."	( Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells. Chang, SJ; Chen, IF; Gao, J; Kuo, SM; Sun, Q; Teong, B, 2014)	0.4
" Besides its effectiveness, it is a poorly water soluble drug with low bioavailability and low half-life (34-90 min), therefore, the development of new formulations of dihydroartemisinin to increase bioavailability is in great need."	( Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations. Bergonzi, MC; Bilia, AR; Coronnello, M; Isacchi, B; Mastrantoni, A; Mini, E; Righeschi, C, 2014)	0.4
"Coadministration of dihydroartemisinin-piperaquine (DHA-PQ) with fat may improve bioavailability and antimalarial efficacy, but it might also increase toxicity."	( Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Batty, KT; Benjamin, JM; Davis, TM; Ginny, E; Griffin, S; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P, 2014)	0.4
" The metabolic capability could recover after a 12-h dosing interval, which suggested that the alternative common three-day regimen (once daily) for DHA-PQ could probably lead to higher bioavailability of DHA."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.4
" Malaria increased the absolute oral bioavailability of artesunate by 87%, presumably by inhibiting first pass effect, whereas pregnancy decreased oral bioavailability by 23%."	( Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Day, NP; Hanpithakpon, W; Hlaing, N; Kloprogge, F; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; Than, HH; White, NJ; Zin, NT, 2015)	0.42
"The population pharmacokinetic analysis demonstrated opposite effects of malaria and pregnancy on the bioavailability of orally administered artesunate."	( Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Day, NP; Hanpithakpon, W; Hlaing, N; Kloprogge, F; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Tarning, J; Than, HH; White, NJ; Zin, NT, 2015)	0.42
"001) in association with a greater clearance relative to bioavailability (73."	( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015)	0.42
" This likely reflects an increase in the oral bioavailability of the drug, directly related to the fat content of the meal."	( Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Bacchieri, A; Evans, AM; Francis, B; Lungershausen, Y; Pace, S; Reuter, SE; Shakib, S; Ubben, D; Valentini, G, 2015)	0.42
"The use of dihydroartemisinin (DHA) for effective malaria treatment is challenged by its poor aqueous solubility and inadequate bioavailability leading to treatment failures and emergence of resistant strains."	( Development Insights of Surface Modified Lipid Nanoemulsions of Dihydroartemisinin for Malaria Chemotherapy: Characterization, and in vivo Antimalarial Evaluation. Attama, A; Chukwuka, R; Obachie, O; Umeyor, CE, 2019)	0.51
"Magnetic DHA nano-liposomes (DHA-MLPs) were developed to improve the targeting antitumor efficiency and bioavailability of DHA, and their physical properties were characterized."	( Effects of magnetic dihydroartemisinin nano-liposome in inhibiting the proliferation of head and neck squamous cell carcinomas. Li, H; Li, X; Li, Z; Shi, X; Sun, Y, 2019)	0.51
" However, it is associated with some limitations, such as low bioavailability which is hampered by its poor aqueous solubility and its rapid metabolism in systemic circulation."	( Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cells. Kumar, R; Meena, J; Panda, AK; Saneja, A; Singh, M; Singhvi, P; Thiyagarajan, D, 2019)	0.51
" They also showed exceptionally better treatment of malaria owing to their sustained release properties and improved bioavailability and are recommended to Pharmaceutical companies for further studies."	( Assessment of the Anti-Malarial Properties of Dihydroartemisinin- Piperaquine Phosphate Solid Lipid-Based Tablets. Amarachi, CS; Attama, AA; Onunkwo, GC, 2022)	0.72
" Nevertheless, the poor water solubility and low bioavailability of DHA seriously impede its clinical applications."	( Self-assembly and self-delivery of the pure nanodrug dihydroartemisinin for tumor therapy and mechanism analysis. Bi, J; Feng, X; Li, W; Li, Y; Shi, N; Xie, Z; Zhang, W; Zhu, W, 2023)	0.91

Excerpt	Relevance	Reference
"5 micrograms/ml of DHA was reached at about 3 minutes after dosing and the AUC was 82 mg/L."	( [Pharmacokinetics and metabolism of artesunate in cows]. Huo, JZ; Xia, WJ; Xue, M; Zhou, ZT, 1991)	0.28
" This novel drug delivery system may be an easy and safe way to administer artemisinin-type antimalarials and also a good alternative dosage form for active compounds with solubility problems."	( Antimalarial activity of dihydroartemisinin derivatives by transdermal application. Ager, AL; Klayman, DL; Lin, AJ, 1994)	0.29
" A suppository of QHS, a dual-pack dosage form of ATS (artesunic acid to be dissolved in sodium bicarbonate solution just before iv injection) and an oil solution of ATM for im injection had been approved by our Ministry of Health for clinical use."	( [Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu]. Song, ZY; Zhao, KC, 1993)	0.29
" A significant therapeutic problem is a high, late recrudescence rate, probably due to short half-lives of both artesunate and its active metabolite dihydroartemisinin relative to conventional dosing intervals."	( Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. Batty, KT; Davis, ME; Davis, T; Ilett, KF, 1996)	0.29
" berghei (with 3/8 cured) superior to that of artelinic acid (1/8 cured), whereas p-fluorophenyl and p-methoxyphenyl analogs demonstrated activity only comparable (1/8 cured) to that of artelinic acid at the same dosage level (64 mg/kg twice a day)."	( Antimalarial activity of new dihydroartemisinin derivatives. 7. 4-(p-substituted phenyl)-4(R or S)-[10(alpha or beta)-dihydroartemisininoxy]butyric acids. Kyle, DE; Lin, AJ; Zikry, AB, 1997)	0.3
" Plasma was separated from blood samples collected at different times after dosing and analysed for parent drug."	( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998)	0.3
"5) hours after dosing [median (range)]."	( Pharmacokinetics and ex vivo anti-malarial activity of sera following a single oral dose of dihydroartemisinin in healthy Thai males. Congpoung, K; Karbwang, J; Na-Bangchang, K; Tan-anya, P; Thanavibul, A; Ubalee, R, 1997)	0.3
" The dosage was 60 mg daily or 2 mg/kg for paediatric patients for 7 successive days with the first dose doubled."	( [Efficacy of dihydroartemisinin in treatment of 37 malaria cases]. Ding, Y; Qi, Z; Xu, C, 1997)	0.3
" For monotherapeutic regimen(s) of DHA, dosing frequency of at least twice a day is suggested."	( Phamacokinetics of a single oral dose of dihydroartemisinin in Vietnamese healthy volunteers. Karbwang, J; Le, NH; Le, TD; Na-Bangchang, K; Thrinh, KA, 1999)	0.3
" Thus, the use of conventional oral dosage regimens of ARTS appears preferable to oral administration of DHA."	( Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Batty, KT; Davis, TM; Iletr, KE; Martin, J; Powell, SM, 2002)	0.31
" Dose-response curves for a Plasmodium falciparum clone (clone W2) and DHA were used as a standard for each assay."	( Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Brewer, TG; Kyle, DE; Peggins, JO; Teja-Isavadharm, P; Webster, HK; White, NJ, 2004)	0.32
"The current dosage of DP (6."	( Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley, EA; Brockman, A; Hutagalung, R; Krudsood, S; Leowattana, W; Looareesuwan, S; McGready, R; Nosten, F; Phaiphun, L; Srivilairit, S; White, NJ; Wilairatana, P, 2004)	0.32
"7 hours on day 4 for both dosage regimens."	( Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria. Chalearmrult, K; Krudsood, S; Li, Q; Looareesuwan, S; Lugt, CB; Milhous, WK; Vannaphan, S; Wilairatana, P, 2004)	0.32
" Two dosage regimens were tested: prophylaxis and treatment."	( Treatment of malaria in a mouse model by intranasal drug administration. Godin, B; Golenser, J; Touitou, E; Waknine, JH, 2006)	0.33
" To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose."	( The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Barnes, KI; Chierakul, W; Evans, AC; Newton, PN; Ruangveerayuth, R; Smith, PJ; White, NJ, 2006)	0.33
"Antimalarial treatment strategies based on in vitro studies are limited by the paucity of pharmacodynamic information for dosage regimen design."	( Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Barrett, PH; Batty, KT; Davis, TM; Gibbons, PL; Ilett, KF, 2007)	0.34
" The dosing regimen has been simplified from four doses to once daily over 3 days."	( Efficacy and safety of dihydroartemisinin-piperaquine. Ashley, EA; Day, NP; Myint, HY; Nosten, F; White, NJ, 2007)	0.34
" We summarized the data under the following themes: content and dissolution; relative bioavailability of antimalarial products; antimalarial stability and shelf life; general tests on pharmaceutical dosage forms; and the presence of degradation or unidentifiable impurities in formulations."	( Antimalarial drug quality in Africa. Amin, AA; Kokwaro, GO, 2007)	0.34
" The review highlights the common finding in drug quality studies that (i) most antimalarial products pass the basic tests for pharmaceutical dosage forms, such as the uniformity of weight for tablets, (ii) most antimalarial drugs pass the content test and (iii) in vitro product dissolution is the main problem area where most drugs fail to meet required pharmacopoeial specifications, especially with regard to sulfadoxine-pyrimethamine products."	( Antimalarial drug quality in Africa. Amin, AA; Kokwaro, GO, 2007)	0.34
" After dose range study, rats were dosed at either 160 mg/kg daily for 9 consecutive days or at 288 mg/kg once every other day for five doses, so that the total dose (1440 mg/kg) and duration (9 days) were identical."	( Neurotoxicity and toxicokinetics of artelinic acid following repeated oral administration in rats. Bennett, K; Johnson, TO; Li, Q; Mog, S; Si, Y; Weina, PJ; Xie, L, )	0.13
"The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized."	( Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Ashley, EA; Ashton, M; Day, NP; Lindegardh, N; McGready, R; Nosten, F; Phaiphun, L; Stepniewska, K; Tarning, J; White, NJ, 2008)	0.35
" However, AL has several limitations, including a twice-daily dosing regimen, recommendation for administration with fatty food, and a high risk of reinfection soon after therapy in high transmission areas."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.35
"DP is highly efficacious, and operationally preferable to AL because of a less intensive dosing schedule and requirements."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.35
"Groups of up to 15 pregnant females were dosed on Gestation Days (GD) 20-50 or for 3-7-day intervals."	( Artesunate: developmental toxicity and toxicokinetics in monkeys. Arima, A; Bernard, F; Clark, RL; Gristwood, W; Harrell, A; Makori, N; Nakata, Y; White, TE; Wier, PJ, 2008)	0.35
"Artesunate was embryolethal at > or =12 mg/kg/day when dosed for at least 12 days at the beginning of organogenesis, but not when dosed for 3 or 7 days, indicating that developmental toxicity of artesunate is dependent upon duration of dosing in cynomologus monkeys."	( Artesunate: developmental toxicity and toxicokinetics in monkeys. Arima, A; Bernard, F; Clark, RL; Gristwood, W; Harrell, A; Makori, N; Nakata, Y; White, TE; Wier, PJ, 2008)	0.35
" C(max) and AUC of artesunate and DHA following iv dosing were 5784 +/- 3718 and 140 938 +/- 128 783 ng."	( Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica. Decosterd, L; Gruyer, MS; Keiser, J; Mercier, T; Perrottet, N; Zanolari, B, 2009)	0.35
" For CCG and MADDS, small to moderate increases in exposure with artesunate dosing were observed."	( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009)	0.35
"A single-center, randomized, single-blind, cross-over clinical study was conducted in 18 healthy volunteers with a dosage of 300 mg daily for 2 days."	( Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. Atipas, S; Chatsiricharoenkul, S; Kaewkungwal, J; Khuhapinant, A; Kongpatanakul, S, 2009)	0.35
" However, children, compared to the population mean profile, tend to have a smaller central volume of distribution, a shorter distribution half-life and a more rapid fall in early piperaquine plasma concentrations, suggesting that an increase of the weight-adjusted dosage in children may be required."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.35
"The dosage recommended for children may need to be reviewed and the usefulness of the coadministration with food should be determined."	( Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro, U, 2009)	0.35
"A novel parent-metabolite pharmacokinetic model consisting of a dosing compartment, a central compartment for AS, a central compartment and a peripheral compartment for DHA was developed."	( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009)	0.35
" falciparum malaria in central Sudan, although treatment with DHA-P (which requires a simpler dosing regimen) might be preferred to treatment with AL."	( Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Adam, I; Elhassan, AH; Elmardi, KA; Eltahir, HG; Malik, EM; Salah, MT, 2010)	0.36
" These findings outline the relevance of DHA dosage and timing to prevent embryotoxicity and support current WHO recommendations of avoiding malaria treatment with artemisinins during the first trimester of pregnancy."	( Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Cappellini, MD; Cattaneo, A; Colancecco, A; Finaurini, S; Ronzoni, L; Taramelli, D; Ward, SA, 2010)	0.36
"Rats were dosed orally with chlorproguanil/dapsone/artesunate (including 11."	( Localization of artesunate and its derivatives in the pregnant rat and fetus following oral administration and relationship to developmental toxicity. Clark, RL; Gristwood, WE; Harrell, AW; Lewsley, R; Wilson, R, 2010)	0.36
" It may also allow a reduction in dosage and a decrease in systemic toxicity."	( Dihydroartemisinin loaded nanostructured lipid carriers (DHA-NLC): evaluation of pharmacokinetics and tissue distribution after intravenous administration to rats. Dong, H; Liu, J; Ni, J; Qiao, H; Shen, C; Shi, Y; Xu, Y; Zhang, X, 2010)	0.36
" CQ showed a delayed dose-response relationship in the murine malaria model and additive efficacy when combined with DHA."	( Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M; Stoney, JR, 2011)	0.37
" The data are reassuring regarding current dosing recommendations."	( Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Hanpithakpon, W; Hlaing, N; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Singhasivanon, P; Tarning, J; Than, HH; White, NJ; Zin, NT, 2012)	0.38
" A three-day course of total 8 tablets compound dihydroartemisinin-piperaquine was administered to an adult (each tablet containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate), dosage for children was based on ages (details in the treatment regimen) ."	( [Efficacy of compound dihydroartemisinin/piperaquine in treatment of uncomplicated falciparum malaria in Myanmar]. Li, CF; Liu, H; Nie, RH; Wang, HY; Yang, HL; Zhang, J, 2011)	0.37
" In the three AL body weight dosing groups (5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months, respectively."	( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011)	0.37
"Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability."	( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011)	0.37
" However, the observed modest changes probably do not warrant dosage adjustment during co-administration of AL with EFV."	( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012)	0.38
"Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments."	( Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Charman, SA; Gamo-Benito, J; Humberstone, A; Jamsen, KM; McCaw, J; Moehrle, J; Price, RN; Simpson, JA; Smith, K; Zaloumis, S, 2012)	0.38
" Declining plasma concentrations during the repeated dosing have been reported for QHS, artemether and less convincingly for artesunate (ARS)."	( An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat. Du, F; Li, X; Xing, J; Zhu, F, 2012)	0.38
" The better safety profile of DP and once-daily dosage improves adherence and its fixed co-formulation ensures that both drugs are taken together."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Aung, K; Mak, JW; Naing, C; Wong, JY, 2013)	0.39
" An adapted dosing regimen including a practical dosing table per weight band is proposed for young children based on the pharmacokinetic model."	( Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Day, NP; Dondorp, AM; Gesase, S; Hendriksen, IC; Kent, A; Lemnge, MM; Lindegardh, N; Mtove, G; Reyburn, H; Tarning, J; von Seidlein, L; White, NJ, 2013)	0.39
" Pre-clinical studies in dogs indicated morbidity at high dosage levels."	( Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Efferth, T; Erich, SA; Fleckenstein, L; Grinwis, GC; London, CA; Mol, JA; Rutteman, GR; Spee, B, 2013)	0.39
" More studies with appropriate control groups in larger series are needed to characterize the degree to which pregnant women are underdosed with current antimalarial dosing regimens."	( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013)	0.39
"Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children."	( The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. , 2013)	0.39
" The better safety profile of DHP and the once-daily dosage improves adherence, and its fixed co-formulation ensures that both drugs (dihydroartemisinin and piperaquine) are taken together."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. Aung, K; Mak, JW; Naing, C; Racloz, V; Reid, SA; Tanner, M; Whittaker, MA, 2013)	0.39
" The dosing schedule is simpler with the artenimol + piperaquine combination than with artemether + lumefantrine."	( Artenimol + piperaquine. Very slow piperaquine elimination: cardiovascular risks and interactions. , 2014)	0.4
" However, the optimal drug and dosing regimens for IPT remain to be determined."	( Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Amuge, P; Brooker, SJ; Dorsey, G; Kamya, MR; Kiwanuka, N; Nankabirwa, JI; Rosenthal, PJ; Staedke, SG; Wandera, B, 2014)	0.4
" The development of appropriate pragmatic dosing regimens for low-resource settings or community-based use is not formally regulated, even though these may alter factors which can substantially affect individual patient and population level outcome, such as drug exposure, patient adherence and the spread of drug resistance and can affect a drug's reputation and its eventual therapeutic lifespan."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.4
"An in silico pharmacological model of anti-malarial drug treatment with the pharmacokinetic/pharmacodynamic profiles of artemether-lumefantrine (AM-LF, Coartem®) and dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) was constructed to assess the potential impact of programmatic factors, including regionally optimized, age-based dosing regimens, poor patient adherence, food effects and drug resistance on treatment outcome at population level, and compared both drugs' susceptibility to these factors."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.4
"Compared with DHA-PPQ, therapeutic effectiveness of AM-LF seems more robust to factors affecting drug exposure, such as age- instead of weight-based dosing or poor adherence."	( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014)	0.4
"This study has developed mechanistic models that describe the parasite-time curve after single, multiple or combination dosing of antimalarials to mice."	( Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. Batty, KT; Gibbons, PL; Kirkpatrick, CM; Moore, BR; Patel, K, 2014)	0.4
" The cases were given a 2-day course with DHAPIP tablets each containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate, and the total dosage varied with the body weight."	( [Therapeutic efficacy and safety of compound dihydroartemisinin/piperaquine for uncomplicated Plasmodium falciparum infection in Laiza City of Myanmar bordering on China]. Deng, Y; Lasi, JH; Sun, XD; Sun, XY; Wang, H; Wang, J; Yang, YC; Zhang, ZX, 2011)	0.37
" The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation."	( Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Auayporn, M; Buathong, N; Cantilena, L; Chann, S; Chour, CM; Haigney, M; Kaewkungwal, J; Kuntawunginn, W; Lanteri, C; Lon, C; Manning, J; Mitprasat, M; Phann, ST; Prom, S; Saunders, D; Se, Y; Sea, D; Siripokasupkul, R; So, M; Soh, E; Somethy, S; Spring, M; Sriwichai, S; Tang, D; Teja-Isavadharm, P; Timmermans, A; Vanachayangkul, P, 2014)	0.4
" However, the optimal chemoprevention drug and dosing strategy is unclear in areas of year-round transmission and resistance to many antimalarial drugs."	( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014)	0.4
" This result relies on the assumption that compliance to treatment with DhP is higher than that with AL due to its relatively simple once-a-day dosage regimen."	( Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Mori, AT; Ngalesoni, F; Norheim, OF; Robberstad, B, 2014)	0.4
" Due to auto-induction metabolism, declining plasma concentrations after the repeated dosing have been reported for artemisinin (Qing-hao-su) and artemether."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.4
" The metabolic capability could recover after a 12-h dosing interval, which suggested that the alternative common three-day regimen (once daily) for DHA-PQ could probably lead to higher bioavailability of DHA."	( The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine. Li, X; Liu, H; Xing, J; Yang, A; Zang, M; Zhao, L; Zhu, F, 2014)	0.4
"Adherence to anti-malarial dosing schedules is essential to ensure effective treatment."	( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study. Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015)	0.42
" While the sweet taste of dispersible AL may have reduced conflict between the child and caregiver, sub-optimal dosing due to medication loss remained a problem and overall adherence was greater among those receiving DHA-PPQ, which requires fewer doses."	( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study. Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015)	0.42
" Current weight-based dosing does not adequately address physiological changes in early childhood."	( Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. Arinaitwe, E; Aweeka, FT; Bigira, V; Creek, DJ; Kakuru, A; Lindegardh, N; McCormack, SA; Nosten, F; Parikh, S; Sambol, NC; Tappero, JW; Tarning, J; Wanzira, H; Yan, L, 2015)	0.42
" Hence, dosing recommendations cannot be made in infants <5 kg as implications for toxicity are unknown."	( Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®). Alao, MJ; Cousin, M; Duparc, S; Hamed, K; Jain, JP; Lefèvre, G; Lingani, M; Meremikwu, M; Ogutu, B; Ouedraogo, A; Tinto, H; Tiono, AB; Tshefu, A, 2015)	0.42
" In particular, the malaria community may be missing the opportunity to dramatically increase ACT effectiveness through regimen changes, particularly through a switch to twice-daily regimens and/or increases in artemisinin dosing levels."	( How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance? Hastings, IM; Hodel, EM; Kay, K, 2015)	0.42
" Children were randomized at 6 months of age to no chemoprevention (n = 89) or monthly DHA/PQ (n = 87) and followed through 24 months of age, with pharmacokinetic sampling performed at variable times following monthly dosing of DHA/PQ."	( Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Aweeka, F; Bigira, V; Dorsey, G; Huang, L; Jagannathan, P; Kakuru, MM; Kamya, MR; Kapisi, J; Savic, R; Sundell, K, 2015)	0.42
" Strategies to ensure good adherence to monthly dosing and optimize drug exposure are critical to maximize the efficacy of this promising malaria control strategy."	( Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Aweeka, F; Bigira, V; Dorsey, G; Huang, L; Jagannathan, P; Kakuru, MM; Kamya, MR; Kapisi, J; Savic, R; Sundell, K, 2015)	0.42
" There were fewer concerns about treatment, mostly because of the simpler dosing regimen of the study drug (dihydroartemisinin-piperaquine) compared to the current first-line treatment (artemether-lumefantrine)."	( Community perceptions of mass screening and treatment for malaria in Siaya County, western Kenya. Allen, DR; Awino, N; Desai, M; Kariuki, S; Ouma, P; Samuels, A; Shuford, K; Were, F, 2016)	0.43
" This therapeutic failure with DP by under-dosing highlighted the importance of appropriate dosing guidelines and the need of research data (efficacy, pharmacokinetics and pharmacodynamics) in over-weight patient group."	( Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Javelle, E; Madamet, M; Paleiron, N; Pradines, B; Roseau, JB; Simon, F; Vedy, S, 2016)	0.43
" This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials."	( Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Bergstrand, M; Karlsson, MO; Nosten, F; Permala, J; Tarning, J; White, NJ, 2017)	0.46
"For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing."	( Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. Aweeka, F; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kakuru, A; Kamya, M; Muhindo, M; Nakalembe, M; Natureeba, P; Rosenthal, PJ; Savic, RM; Vucicevic, K; Wallender, E, 2018)	0.48
" Determining associations between piperaquine (PQ) exposure, malaria risk, and adverse birth outcomes informs optimal dosing strategies."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.48
" Simulations of new dosing scenarios were performed."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.48
" Studies of the efficacy and safety of alternative DHA-PQ IPTp dosing strategies are warranted."	( Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Aweeka, FT; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Muhindo, MK; Mwebaza, N; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Were, M; Zhang, N, 2018)	0.48
" All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre."	( Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. , 2018)	0.48
" We provide published data supporting the use of a higher dosage regimen of ivermectin in malaria and difficult-to-treat head lice, and announce an ongoing randomized clinical trial in severe scabies."	( High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug. Bernigaud, C; Chosidow, O; Do-Pham, G, 2018)	0.48
"Nous soulignons l’absence de données probantes de haut niveau sur les études de dosage concernant l’utilisation de l’ivermectine par voie orale dans les maladies parasitaires sensibles."	( High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug. Bernigaud, C; Chosidow, O; Do-Pham, G, 2018)	0.48
" Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy."	( Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. Aweeka, F; Beeson, J; Charlebois, ED; Clark, TD; Dorsey, G; Drakeley, C; Feeney, ME; Greenhouse, B; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nakalembe, M; Nankya, F; Natureeba, P; Okiring, J; Olwoch, P; Opira, B; Prahl, M; Reiling, L; Rodriguez-Barraquer, I; Ssewanyana, I; Tetteh, K; Wallender, E, 2018)	0.48
" falciparum intraerythrocytic stage were observed, and then the 3D7 life cycle and effects of different developmental stages after dosing was explored."	( [Effect of dihydroartemisinin at low concentration on intervention of Plasmodium falciparum 3D7 strain]. Chen, LN; Guo, Y; Jiang, XH; Li, K; Li, YJ; Yang, T; Zheng, XJ; Zheng, ZY, 2018)	0.48
" The favourable biodistribution and tumour uptake of NCPs and the absence of peripheral neuropathy allow for repeated dosing to afford 100% tumour eradication."	( Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Chan, C; Duan, X; Guo, N; Han, W; Lin, W; Weichselbaum, RR, 2019)	0.51
"Dihydroartemisinin (DHA)-piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children."	( Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Aweeka, FT; Chamankhah, N; Dorsey, G; Huang, L; Jagannathan, P; Kajubi, R; Kamya, MR; Mwebaza, N; Orukan, F; Rosenthal, PJ; Wallender, E; Whalen, ME, 2019)	0.51
" However, the optimal dosing strategy is unclear and conflicting evidence exists regarding the risk of malaria after cessation of chemoprevention."	( Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial. Charlebois, E; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nalugo, N; Okiring, J; Olwoch, P; Opira, B; Ruel, T, 2019)	0.51
"Considering the low day 7 concentrations of piperaquine reported in the patients studied here, we suggest to adopt the recently recommended higher dose of DP in young children or a prolonged 5-day dosing in children living in malaria endemic areas who have suffered an initial episode of severe malaria in order to achieve adequate drug exposures for effective post-treatment prophylactic effects."	( Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine. Blessborn, D; Byakika-Kibwika, P; Lamorde, M; Ssenyonga, R; Tarning, J, 2019)	0.51
" These data suggest that malaria and HIV coinfected pregnant women may require adjustments in AL dosage or treatment duration to achieve exposure comparable with HIV-uninfected pregnant women."	( Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S, 2020)	0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" It is expected that such a tool will be useful in characterizing the disposition of these chemicals and ultimately improve dosing regimens by enabling a quantitative assessment of the tissue-specific drug levels critical in the evaluation of efficacy and toxicity."	( Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling. Arey, R; Reisfeld, B, 2021)	0.62
" Participants in the intermittent preventive malaria treatment arm will receive dihydroartemisinin/piperaquine (DP) dosed by weight, 1 month apart, prior to the first immunisation, followed by monthly treatment thereafter."	( Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the ' Akello, F; Amongi, S; Amongin, R; Cose, S; Elliott, AM; Kabuubi, PN; Kiwanuka, S; Kiwudhu, F; Kizindo, R; Mutebe, A; Nakazibwe, E; Nassuuna, J; Natukunda, A; Nkurunungi, G; Nsubuga, D; Oduru, G; Onen, C; Sewankambo, M; Staedke, SG; Webb, E; Zirimenya, L, 2021)	0.62
" Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences."	( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021)	0.62
" Optimal DP dosing regimens will maximize efficacy and reduce toxicity and resistance selection."	( Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Ali, AM; Aweeka, F; Dorsey, G; Duvalsaint, M; Huang, L; Hughes, E; Jagannathan, P; Kakuru, A; Kamya, MR; Legac, J; Muhindo, MK; Opira, B; Rosenthal, PJ; Savic, RM; Wallender, E; Whalen, M, 2021)	0.62
" Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could lead to progressive QTc prolongation."	( Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Aweeka, F; Clark, TD; Dorsey, G; Hughes, E; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Ochieng, T; Rosenthal, PJ; Savic, RM; Wallender, E, 2022)	0.72
"Repeated DHA-PQ dosing did not result in increased risk of QTc prolongation and the postdose QTc intervals progressively decreased."	( Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Aweeka, F; Clark, TD; Dorsey, G; Hughes, E; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Ochieng, T; Rosenthal, PJ; Savic, RM; Wallender, E, 2022)	0.72
" Participants were randomly assigned (1:1:1:1) to standard treatment with dihydroartemisinin-piperaquine, or dihydroartemisinin-piperaquine plus a single dose of tafenoquine (in solution) at a final dosage of 0·42 mg/kg, 0·83 mg/kg, or 1·66 mg/kg."	( Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF, 2022)	0.72
" Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether-lumefantrine or dihydroartemisinin-piperaquine, dosed by bodyweight."	( Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n Abongo, G; Basara, BB; Baseke, J; Bongo, GS; Day, NJP; Dhorda, M; Dondorp, AM; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Peerawaranun, P; Tarning, J; Taya, C; Taylor, WR; Titin, H; Uyoga, S; Waithira, N; Weere, W; Williams, TN, 2023)	0.91
" Better dosing regimens are needed to optimize malaria prevention in malnourished populations, but, importantly, malaria chemoprevention may reduce the burden of malnutrition in early childhood."	( Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis. Ali, AM; Dorsey, G; Hughes, E; Savic, RM; Wallender, E, 2023)	0.91
" We will also assess toxicity from cumulative DP dosing and the development of resistance."	( Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-contro Akun, P; Galileya, LT; Idro, R; Kalibbala, D; Nambatya, W; Nkosi-Gondwe, T; Opoka, R; Phiri, K; Robberstad, B; Rujumba, J; Ssenkusu, J; TerKuile, F, 2023)	0.91

Class	Description
artemisinin derivative	Any organic peroxide formally obtained from artemisinin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	125.0000	0.0001	1.7536	10.0000	AID1212138
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	125.0000	0.0011	3.4186	10.0000	AID1212134
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (807)

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1609530	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1733061	Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity.
AID1609531	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1609535	Antitumour activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as reduction in tumour growth at 10 mg/kg, ip administered daily for 18 days started from 2 days after tumor cell inoculation by digital caliper method	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1733062	Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity.
AID1655967	Inhibition of human TOP1B expressed in Saccharomyces cerevisiae EKY3 lacking top1 assessed as reduction in yeast cell growth at 30 uM	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1.
AID1401025	Antiproliferative activity against human NB4 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1648007	Cytotoxicity against HEK293 cells assessed as growth inhibition at 20 uM relative to control	2020	Journal of natural products, 02-28, Volume: 83, Issue:2	A Meroisoprenoid, Heptenolides, and
AID1326706	Cytotoxicity against human HL60 cells assessed as cell growth inhibition at 10 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1441235	Antimalarial activity against quinine-resistant asexual blood stage Plasmodium falciparum 3D7 after 72 hrs by SYBR green-based fluorometric analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1326702	Cytotoxicity against human LS180 cells assessed as cell growth inhibition at 30 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1272409	Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as permeability across apical to basolateral after 90 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1888544	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as food intake at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1357959	Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay
AID1777162	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 incubated for 72 hrs by spectrophotometry based parasite lactate dehydrogenase assay	2021	ACS medicinal chemistry letters, Jul-08, Volume: 12, Issue:7	Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.
AID1327394	Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1888546	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in TC concentration in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1782711	Antimalarial activity against Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 48 hrs by SYBR green DNA fluorescent dye-binding assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.
AID1708863	Antiplasmodial activity against Plasmodium falciparum GB4 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1545819	Antiproliferative activity against human HL60 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1326716	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1326747	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential at 5 uM after 24 hrs by Rh123 dye-based FACS analysis (Rvb = 5%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1272411	Permeability across apical to basolateral side in MDCK cells after 90 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1437506	Selectivity index, ratio of growth inhibitory effect against HEK293 cells at 20 uM to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC
AID1326722	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human HepG2 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888558	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Cyp7b1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1825877	Antimalarial activity against asexual blood stage quinine-resistant Plasmodium falcipuram C2A assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green I staining based fluorescence analysis
AID1274586	Cytotoxicity against HEK293 cells assessed as cell viability at 40 uM after 72 hrs by resazurin-based plate reader analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1888552	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as AST level in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1674381	Antimalarial activity against Plasmodium falcipuram K1 by microculture radioistope technique	2020	Journal of natural products, 07-24, Volume: 83, Issue:7	Highly Modified Lanostane Triterpenes from the Wood-Rot Basidiomycete
AID1812439	Inhibition of human HDAC using human HeLa cell nuclear extract measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1272408	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1779235	Selectivity index, ratio of IC50 for antimalarial activity against Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum 3D7	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1546485	Induction of apoptosis in human PC14 cells assessed as increase in apoptotic cells at 30 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1395097	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1545824	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1441258	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1326731	Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 0.2 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 1 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888543	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as body weight at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1272414	Efflux ratio of permeability across basolateral to apical side over apical to basolateral side in MDCK cells	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1326721	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888573	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Scd1 mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1326735	Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 0.5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 1 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1708858	Antiplasmodial activity against synchronized ring stage Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1810292	Antimalarial activity against chloroquine, pyrimethamine, mefloquine and atovaquone- resistant Plasmodium falciparum TM90-C2B infected in human erythrocytes assessed as reduction in parasite growth incubated for 48 hrs followed by addition of [3H]-hypoxan	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
AID1853165	Selectivity index, ratio of IC50 for Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC to IC50 for Cytotoxicity against human HepG2 cells	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID1326696	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition at 30 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1395044	Inhibition of PDE1 (unknown origin) using [3H]cAMP or [3H]cGMP as substrate liquid scintillation counting method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Inhibitors of phosphodiesterase as cancer therapeutics.
AID1401029	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1825879	Antimalarial activity against asexual blood stage wild-type Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green I staining based fluorescence analysis
AID1326713	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human MIAPaCa2 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1545821	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1441256	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1326708	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human HL60 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1727378	Parasiticidal activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasitemia at 50 nM incubated for 24 to 48 hrs followed by compound washout and then incubated for 96 hrs by Giemsa staining	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of fast-acting dual-stage antimalarial agents by profiling pyridylvinylquinoline chemical space via copper catalyzed azide-alkyne cycloadditions.
AID1770979	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents.
AID1676920	Antiplasmodial activity against synchronous gametocyte early stage of Plasmodium falciparum 3D7 harboring luc7 incubated for 72 hrs by ONE-Glo luciferase assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1326704	Cytotoxicity against human HL60 cells assessed as cell growth inhibition at 0.5 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1676941	Antiplasmodial activity against synchronized chloroquine-resistant Plasmodium falciparum Dd2 reduction in microbial growth at 50 nM treated with compound at 42 hrs post infection measured after 12 hrs by Giemsa staining-based microscopic analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1274588	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1326703	Cytotoxicity against human LS180 cells assessed as cell growth inhibition at 50 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1573775	Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblasts measured after 7 days by GFP-based multi-round replication assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID1354680	Antiplasmodial activity against Plasmodium falciparum NF54	2018	Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18	Plasmodial Kinase Inhibitors: License to Cure?
AID1497085	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1708866	Antiplasmodial activity against artemisinin-resistant Plasmodium falciparum 6218 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1708860	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1326694	Cytotoxicity against human HL60 cells assessed as cell growth inhibition at 50 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1772149	Antimalarial activity against Plasmodium falciparum K1 assessed as inhibition of parasite growth by microculture radioisotope technique	2021	Journal of natural products, 11-26, Volume: 84, Issue:11	Antimicrobial and Cytotoxic Angucyclic Quinones from
AID1271049	Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1888571	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Fasn mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1489613	Antimalarial activity against mefloquine/chloroquine/atovaquone/pyrimethamine-resistant Plasmodium falciparum TM90-C2B infected in human type A-positive erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1699653	Selectivity index, ratio of IC50 for cytotoxicity against human HEK293 cells to IC50 for antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 ring stage	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Antiplasmodial Alkaloids from the Australian Bryozoan
AID1457810	Antiplasmodial activity against Plasmodium falciparum Cam3.2 infected in human RBC assessed as time required to reduce early ring stage parasite viability by 50% by SYTO 61-staining-based flow cytometry	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID1890799	Inhibition of Th17 cells differentiation in C57BL/6 mouse spleen CD4+ve Th cells assessed as decrease in IL-17A production at 10 uM measured after 4 days by flow cytometry analysis
AID1437499	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID1888578	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in Srebf1 mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1327390	Antiplasmodial activity against chloroquine-resistant asexual erythrocyte stage form Plasmodium falciparum Dd2 measured after 48 hrs by pLDH assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1888568	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in Slc10a2 mRNA expression in Ileum at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1708864	Antiplasmodial activity against Plasmodium falciparum C2A infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1612608	Antimalarial activity against ring-stage multidrug-resistant Plasmodium falciparum Dd2 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents.
AID1699650	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 ring stage incubated for 72 hrs by DAPI-staining based imaging analysis	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Antiplasmodial Alkaloids from the Australian Bryozoan
AID1888566	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcb4 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1498473	Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in primary HFF	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1271051	Selectivity index, ratio of IC50 for human L02 cells to IC50 for human A549 cells	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1810291	Antimalarial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as reduction in parasite growth incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
AID1639284	Antiplasmodial activity against drug-resistant Plasmodium falciparum Dd2 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1890798	Inhibition of Th1 cells differentiation in C57BL/6 mouse spleen CD4+ve Th cells assessed as decrease in IFNgamma production at 10 uM measured after 4 days by flow cytometry analysis relative to control
AID1673893	Selectivity ratio of IC50 for human IOSE144 cells to IC50 for human A2780 cells	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Monomeric Targeted Protein Degraders.
AID1873114	Antimalarial activity against Plasmodium falciparum Cam3.I^R539T assessed as inhibition of parasite growth measured after 6 hrs	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Spiral molecules with antimalarial activities: A review.
AID1888574	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Fasn protein expression in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1545511	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green1 dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, May-15, Volume: 170	Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
AID1326741	Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 46 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1497080	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1812445	Inhibition of human recombinant HDAC6 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1326740	Cell cycle arrest in human HL60 cells assessed as accumulation at subG0 phase at 5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 5 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1274390	Antimalarial activity against 4th to 5th gametocyte stage of Plasmodium falciparum 3D7elo1-pfs16-CBG99 assessed as inhibition of gametocyte viability by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1	Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID1612609	Antimalarial activity against ring-stage chloroquine-susceptible Plasmodium falciparum 3D7 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents.
AID1546483	Cytotoxicity against human U251/CP2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1890800	Inhibition of Th17 cells differentiation in C57BL/6 mouse spleen CD4+ve Th cells assessed as decrease in IL-17A production at low concentration measured after 4 days by flow cytometry analysis
AID1770983	Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents.
AID1271047	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1326697	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition at 50 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888553	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as ldlr-mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1327392	Cytotoxicity against human WI38 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1395100	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1545930	Antiproliferative activity against human KB cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1489616	Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1812436	Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1888550	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in size of lipid droplet concentration in serum at 150 mg/kg, ig for 4 weeks by H and E staining based assay	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1395101	Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1395099	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1441260	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1440393	Antibiofilm activity against Candida albicans SC5314 after 24 hrs in presence of miconazole by Cell-Titer Blue assay	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Tackling Fungal Resistance by Biofilm Inhibitors.
AID1699649	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 ring stage incubated for 72 hrs by DAPI-staining based imaging analysis	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Antiplasmodial Alkaloids from the Australian Bryozoan
AID1583706	Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as reduction in total adult worm burden at 400 mg/kg, po administered as single dose starting on day 49 post-infection and measured at 28 days post treatment relative to	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Structure-Activity Relationship of Antischistosomal Ozonide Carboxylic Acids.
AID1326695	Cytotoxicity against human HL60 cells assessed as cell growth inhibition at 30 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1401024	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1779234	Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1401023	Antiproliferative activity against human U937 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1489612	Antimalarial activity against pyrimethamine/chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1888560	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcg5 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1272410	Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as permeability across basolateral to apical after 90 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1326701	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition at 50 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1699652	Selectivity index, ratio of IC50 for cytotoxicity against human HEK293 cells to IC50 for antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 ring stage	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Antiplasmodial Alkaloids from the Australian Bryozoan
AID1357960	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay
AID1888551	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as ALT level in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1457833	Antiplasmodial activity against Plasmodium falciparum Cam3.2_rev infected in human RBC assessed as time required to reduce early ring stage parasite viability by 50% by SYTO 61-staining-based flow cytometry	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.
AID1562839	Solubility of compound in water	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity.
AID1401028	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1545825	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1326732	Cell cycle arrest in human HL60 cells assessed as accumulation at subG0 phase at 0.5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 5 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1504889	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1888554	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as hmgcr-mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1271050	Cytotoxicity against human L02 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1401022	Antiproliferative activity against human HL60 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1888555	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as Cyp39a1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1357958	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay
AID1648008	Selectivity ratio of IC50 for HEK293 cells to IC50 for antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2	2020	Journal of natural products, 02-28, Volume: 83, Issue:2	A Meroisoprenoid, Heptenolides, and
AID1888564	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Slcob2 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1699658	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 0.1 uM after 72 hrs by resazurin dye based assay	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Antiplasmodial Alkaloids from the Australian Bryozoan
AID1770986	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents.
AID1327395	Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1326698	Cytotoxicity against human PC3 cells assessed as cell growth inhibition at 30 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1626152	Cytotoxicity against mouse J774 cells	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1327391	Resistance index, ratio of IC50 for chloroquine-resistant asexual erythrocyte stage form Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1272413	Activity at MDR1 (unknown origin) expressed in MDCK cells assessed as efflux ratio of permeability across basolateral to apical side over apical to basolateral side	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1888572	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in SCD1 protein expression in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1782709	Inhibition of recombinant Plasmodium falciparum falcipain-2 expressed in Escherichia coli M15 assessed as reduction in free AMC release using Z-FR-AMC as a substrate measured over 30 mins by fluorometric assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.
AID1327389	Antiplasmodial activity against chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54 measured after 48 hrs by pLDH assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1545820	Antiproliferative activity against mouse P388 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1545826	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1354693	Inhibition of Plasmodium falciparum 3D7 6xHis-tagged PI3K helica domain expressed in Escherichia coli by Western blot analysis	2018	Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18	Plasmodial Kinase Inhibitors: License to Cure?
AID1888556	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as Cyp7a1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1812456	Antiplasmodial activity against synchronized ring stage Plasmodium falciparum 3D7 assessed as parasite reduction rate in lag phase by measuring time required to achieve maximum speed of action at 10 times IC50 concentration	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1274589	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1890797	Inhibition of Th1 cells differentiation in C57BL/6 mouse spleen CD4+ve Th cells assessed as decrease in IFNgamma production at low concentration measured after 4 days by flow cytometry analysis
AID1326737	Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 1 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 46 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1401026	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1574646	Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based confocal imaging analysis	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1326739	Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 1 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 1 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1545817	Antiproliferative activity against human MCF7 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1626149	Antimalarial activity against Plasmodium falciparum W2	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1326727	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human LS180 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1779233	Antimalarial activity against synchronous ring stage of Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1504885	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1888557	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as Cyp46a1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1545831	Antiproliferative activity against human HepG2 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1888575	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in CD36 mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1546480	Induction of apoptosis in human U937 cells assessed as increase in apoptotic cells at 60 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1437503	Growth inhibition of HEK293 cells at 20 uM after 72 hrs by PrestoBlue staining based fluorescence assay relative to control
AID1574648	Growth inhibition of HEK293 cells at 10 uM after 72 hrs by resazurin dye based assay relative to control	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1673905	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Monomeric Targeted Protein Degraders.
AID1326744	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential at 0.2 uM after 24 hrs by Rh123 dye-based FACS analysis (Rvb = 5%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1485911	Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis of nοvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents.
AID1327387	Thermal stability of the compound assessed as onset of decomposition temperature by thermogravimetric analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1648003	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay	2020	Journal of natural products, 02-28, Volume: 83, Issue:2	A Meroisoprenoid, Heptenolides, and
AID1812457	Antiplasmodial activity against synchronized ring stage Plasmodium falciparum 3D7 assessed as parasite reduction over one cycle upto 48 hrs at 10 times IC50 concentration	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1573776	Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in type A-positive human erythrocytes after 72 hrs by SYBR green 1 dye-based fluorescence assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID1545822	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1354698	Antiplasmodial activity Plasmodium berghei infected in ip dosed mouse	2018	Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18	Plasmodial Kinase Inhibitors: License to Cure?
AID1272412	Permeability across basolateral to apical side in MDCK cells after 90 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells.
AID1401031	Selectivity ratio of GI50 for human MCF7 cells to GI50 for human MCF7/ADR cells	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1779232	Antimalarial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite growth measured after 72 hrs by Monash assay based fluorescence analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1504883	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based confocal microplate imaging method	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1545818	Antiproliferative activity against human Lu1 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1888561	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcg8 protein expression in liver in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1326700	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition at 30 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888579	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in ACACa protein expression in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1271048	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1812435	Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1441261	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite cure level at 10 to 90 mg/kg, ip administered on days 1 post infection by Giemsa-stained microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1708867	Antiplasmodial activity against artemisinin-resistant ring stage Plasmodium falciparum 6320 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1326742	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 53 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1271044	Drug degradation at 2 to 4 mg at 210 to 220 degC by thermogravimetric analysis in the presence of nitrogen gas	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1825886	Antimalarial activity against asexual blood stage chloroquine-resistant Plasmodium falcipuram GB4 assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green I staining based fluorescence analysis
AID1327388	Thermal stability of the compound assessed as melting point by thermogravimetric analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1639289	Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence assay relative to control	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1326717	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human PC3 cells	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1676947	Parasiticidal activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in RBC assessed as reduction in parasitemia at 50 nM incubated for 6 to 48 hrs followed by compound washout and then incubated for 96 hrs by Giemsa staining based micr	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1812444	Inhibition of human recombinant HDAC3 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1639283	Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1271046	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.
AID1395098	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1401027	Antiproliferative activity against human LNCAP cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1708857	Antiplasmodial activity against synchronized ring stage Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1326738	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 1 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 53 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1574645	Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based confocal imaging analysis	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1545823	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1673894	Selectivity ratio of IC50 for human IOSE144 cells to IC50 for human OVCAR3 cells	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Monomeric Targeted Protein Degraders.
AID1326728	Cell cycle arrest in human HL60 cells assessed as accumulation at subG0 phase at 0.2 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 5 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1782710	Inhibition of recombinant Plasmodium falciparum falcipain-2 expressed in Escherichia coli M15 assessed as reduction in free AMC release using Z-FR-AMC as a substrate measured over 30 mins by Cheng-prusoff equation analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.
AID1673904	Growth inhibition of human A2780 cells incubated for 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Monomeric Targeted Protein Degraders.
AID1326734	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 0.5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 53 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1777163	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 incubated for 72 hrs by spectrophotometry based parasite lactate dehydrogenase assay	2021	ACS medicinal chemistry letters, Jul-08, Volume: 12, Issue:7	Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205.
AID1497081	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1888569	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in Slc51b mRNA expression in Ileum in at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1546482	Cytotoxicity against human U373 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1485903	In vivo antiangiogenic activity in Leghorn chicken embryo chorioallantoic membrane assessed as decrease in total vessel length at 10 nmol/egg after 48 hrs relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis of nοvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents.
AID1546479	Induction of apoptosis in rat C6 cells assessed as apoptotic cells at 200 uM after 24 hr in presence of holo-transferrin by Annexin V-FITC/propidium iodide staining based flow cytometric analysis relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1441257	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1326730	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 0.2 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 53 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1441259	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1648004	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by DAPI staining based fluorescence assay	2020	Journal of natural products, 02-28, Volume: 83, Issue:2	A Meroisoprenoid, Heptenolides, and
AID1497084	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1326750	Induction of apoptosis in human HL60 cells assessed as induction of apoptotic bodies at 0.5 uM after 24 hrs by hoechst 33258 staining-based microscopic analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1770984	Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents.
AID1395102	Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
AID1326736	Cell cycle arrest in human HL60 cells assessed as accumulation at subG0 phase at 1 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 5 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1326745	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential at 0.5 uM after 24 hrs by Rh123 dye-based FACS analysis (Rvb = 5%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1825880	Antimalarial activity against asexual blood stage chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green I staining based fluorescence analysis
AID1355623	Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblast assessed as reduction in virus-induced cytopathic effect after 7 days
AID1708865	Antiplasmodial activity against Plasmodium falciparum CP286 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by Giemsa staining based light microscopic method	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	Discovery of Novel
AID1853163	Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID1357961	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay
AID1437497	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID1498471	Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1546484	Induction of apoptosis in human HCT116 cells assessed as increase in apoptotic cells at 40 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1812458	Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as time to kill initial parasite load at 10 times IC50 concentration	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1326707	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1676949	Antiplasmodial activity against synchronous gametocyte late stage of Plasmodium falciparum 3D7 harboring luc7 incubated for 72 hrs by ONE-Glo luciferase assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1639290	Selectivity ratio of IC50 for Plasmodium falciparum Dd2 ring stage forms to IC50 for Plasmodium falciparum 3D7 ring stage forms	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1888559	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcg8 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1274587	Cytotoxicity against HEK293 cells assessed as cell viability at 20 uM after 72 hrs by resazurin-based plate reader analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1562838	Elimination half-life in Sprague-Dawley rat at 10 mg/kg administered as iv bolus dose by EC-HPLC analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity.
AID1504881	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based confocal microplate imaging method	2017	Journal of natural products, 12-22, Volume: 80, Issue:12	Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1812434	Antiplasmodial activity against asynchronous asexual culture of Plasmodium falciparum NF54 assessed as parasite growth inhibition	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1441254	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1497079	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1825887	Antimalarial activity against asexual blood stage sulfadoxine-pyrimethamine/mefloquine-resistant Plasmodium falcipuram CP286 assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green I staining based fluorescence analysis
AID1326754	Lipophilicity, log P of the compound	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1639288	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-sensitive Plasmodium falciparum 3D7 ring stage forms	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1441255	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1638553	Antimalarial activity against Plasmodium berghei infected in mouse inoculated with Plasmodium berghei infected RBCs dosed orally starting at 2 hrs after inoculation of infected RBCs followed by same dose administration for 3 more days after each 24 hrs pe	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1326743	Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 1 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1812442	Inhibition of human recombinant HDAC1 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1649432	Antimalarial activity against Plasmodium falciparum clinical isolates measured after 72 hrs by SYBR green dye based fluorescence assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID1441252	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1326712	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888567	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Slc10a1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1888563	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in Abcg1 mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1888562	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcg5 protein expression in liver in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1498470	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1782707	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by WST-1 assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.
AID1888547	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in HDL-C concentration in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1888580	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in CD36 protein expression in liver at 150 mg/kg, ig for 4 weeks by western blot analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1498472	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green dye fluorescence assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1676942	Antiplasmodial activity against synchronized chloroquine-resistant Plasmodium falciparum Dd2 reduction in microbial growth at 50 nM treated with compound at 42 hrs post infection measured after 12 hrs by YOYO-1 staining-based flow cytometric analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1770985	Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents.
AID1326699	Cytotoxicity against human PC3 cells assessed as cell growth inhibition at 50 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1546481	Antitumour activity against human U937 cells xenografted in NOD/SCID mouse assessed as tumor growth inhibition at 50 mg/kg, ip for 20 days relative to control	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Artemisia: a promising plant for the treatment of cancer.
AID1326733	Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 0.5 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 46 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1812441	Inhibition of Plasmodium falciparum NF54 HDAC using extract measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1888577	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Elovl6 mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1326729	Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 0.2 uM after 24 hrs by propidium iodide-DNA fluorescence based FACS analysis (Rvb = 46 %)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1888549	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in number of lipid droplet concentration in liver at 150 mg/kg, ig for 4 weeks by H and E staining based assay	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1888565	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Abcb1a mRNA expression in liver in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1401030	Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.
AID1327393	Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1441253	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1888545	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as TG concentration in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1626150	Antimalarial activity against Plasmodium falciparum TM90-C2B	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1888548	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in LDL-C concentration in serum at 150 mg/kg, ig for 4 weeks	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1812443	Inhibition of human recombinant HDAC2 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1326726	Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1326705	Cytotoxicity against human HL60 cells assessed as cell growth inhibition at 1 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1497083	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1497082	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.
AID1485912	Cytotoxicity against HUVEC assessed as reduction in cell number at 10 uM after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis of nοvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents.
AID1888570	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as decrease in Fabp6 mRNA expression in Ileum in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1888576	Hypocholesterolemic activity in OVX-induced C57BL/6 mouse model assessed as increase in Elovl5 mRNA expression in liver at 150 mg/kg, ig for 4 weeks by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 01-01, Volume: 53	Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile.
AID1326746	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential at 1 uM after 24 hrs by Rh123 dye-based FACS analysis (Rvb = 5%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID674169	Growth inhibition of human SF295 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1126762	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1256 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1191135	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID323681	Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID558828	Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1126759	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 821 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID543636	Antimicrobial activity against Echinococcus multilocularis metacestode assessed as increase in alkaline phosphatase activity at 40 uM after 8 days	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID323684	Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID564237	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425945	Antimalarial activity as parasitaemia against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal single dose 64 hrs post infection (Rvb=2.5%+/-0.5%)	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Pharmacodynamics of doxycycline in a murine malaria model.
AID1762668	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet dye based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID1212143	Induction of CYP2B6 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID558836	Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1212133	Inhibition of CYP2B6 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 10 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID1191138	Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID558840	Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID311446	Antimalarial activity against Plasmodium falciparum K1 by microculture radioisotope assay	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Antimalarial and antituberculous poly-O-acylated jatrophane diterpenoids from Pedilanthus tithymaloides.
AID676638	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in presence of DFOM	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID564290	Antimalarial activity against Plasmodium falciparum HB3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1212122	Chemical stability of the compound in human hepatocyte culture medium assessed as compound remaining at 1 to 50 uM after 24 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID558846	Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID674207	Growth restoration activity in cdc2-1 rad9-deficient Saccharomyces cerevisiae assessed as growth zone at 12.5 to 400 ug/disc incubated at 37 degC for 6 hrs and 28 degC for 2 days	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID236038	Bioavailability obtained after oral administration; Not determined	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID562271	Antimalarial activity against Plasmodium falciparum isolates assessed as parasite growth inhibition after 72 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
AID564307	Antimalarial activity against Plasmodium falciparum W2 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID453388	Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID338835	Cytotoxicity against mouse EAC after 3 days by MTT assay	1993	Journal of natural products, Jun, Volume: 56, Issue:6	Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells.
AID755418	Acute toxicity in bovine EBTr cells at 50 uM after 72 hrs	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID576711	Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID428027	Growth inhibition of adriamycin-resistant mouse P388 cells after 72 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID453402	Antibacterial activity against Escherichia coli ATCC 35218 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID1212121	Cytotoxicity against human hepatocytes assessed as cell viability relative to control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID545362	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum C2 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1126748	Antibacterial activity against duck Escherichia coli assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1244911	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID158856	Inhibitory concentration against Plasmodium falciparum W2 Indochina	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID576724	Antimalarial activity against Plasmodium falciparum D10 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID563111	Antimalarial activity against Plasmodium falciparum IMT Vol harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID761774	Antiplasmodial activity against Plasmodium falciparum K1 after 42 hrs by microdilution method	2013	Journal of natural products, Jul-26, Volume: 76, Issue:7	Bioactive compounds from the roots of Strophioblachia fimbricalyx.
AID636828	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope technique	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Lanostane and hopane triterpenes from the entomopathogenic fungus Hypocrella sp. BCC 14524.
AID1186146	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID428117	Antiparasitic activity as reduced parasitaemia after 36 hrs against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal dosed 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID676995	Selectivity index, ratio of CC50 for human HeLa cells to IC50 for Plasmodium falciparum 3D7 ring stage cells	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID444497	Anticancer activity against human A549 cells by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxoartemisinin.
AID1212154	Induction of CYP2D6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID561064	Antiplasmodial activity against Plasmodium falciparum D6	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID1126747	Antibacterial activity against Escherichia coli assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID325364	Antiparasitic activity against Leishmania donovani in hamster assessed as reduction of spleen parasite burden at 50 mg/kg, po	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID1126754	Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1212157	Induction of UGT2B7 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID1126744	Antibacterial activity against Salmonella assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID564288	Antimalarial activity against Plasmodium falciparum FCR3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID444931	Volume of distribution in Sprague-Dawley rat at 2.5 to 3.5 mg/kg, iv	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID576719	Antimalarial activity against Plasmodium falciparum 7G8 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID564299	Antimalarial activity against Plasmodium falciparum IMT 10354 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428019	Growth inhibition of human HL60 cells at 1 uM after 72 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID755419	Antiviral activity against Bovine viral diarrhea virus Oregon C24V genotype 1 subgenotype b infected in bovine EBTr cells assesed as inhibition of virus-induced cytopathic effect at 20 to 100 uM after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1239475	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID561053	Cmax in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID323685	Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID545360	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID674186	Growth inhibition of human OVCAR3 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1762619	Antimalarial activity against multi drug-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by sci
AID558843	Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1212158	Induction of MDR1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID425758	Antimalarial activity as reduced parasitaemia after 24hrs against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal single dose 64 hrs post infection	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Pharmacodynamics of doxycycline in a murine malaria model.
AID1252953	Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID674197	Growth inhibition of human MKN45 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1752549	Antimalarial activity against chloroquine-sensitive plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition measured after 72 hrs by SYBR green dye based fluorescence analysis	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	Preparation, biological & cheminformatics-based assessment of N
AID564302	Antimalarial activity against Plasmodium falciparum IMT K14 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545393	Half life in in children with uncomplicated falciparum malaria at 32 to 35 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID595427	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as reduction in uptake of [3H]-hypoxanthine by microculture radioisotope technique	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Cytotoxic pentacyclic and tetracyclic aromatic sesquiterpenes from Phomopsis archeri.
AID361324	Induction of apoptosis in human HL60 cells assessed as mitochondrial membrane depolarization at 10 uM after 24 hrs by flow cytometry in presence of Z-VAD-fmk	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID84804	Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells.
AID380092	Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine uptake	2006	Journal of natural products, Feb, Volume: 69, Issue:2	A cyclopeptide from the Insect pathogenic fungus Cordyceps sp. BCC 1788.
AID414404	Cytotoxicity against human HT29-AK cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Antitumour and antimalarial activity of artemisinin-acridine hybrids.
AID311558	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope assay	2007	Journal of natural products, Oct, Volume: 70, Issue:10	Antimalarial benzoquinones from an endophytic fungus, Xylaria sp.
AID547315	Antimalarial activity against Plasmodium falciparum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID545379	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring D10 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID453399	Antifungal activity against Aspergillus fumigatus ATCC 90906 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID1212152	Induction of CYP2C19 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID279315	Inhibition of Plasmodium falciparum AZ10011008 isolate in HRP2 ELISA	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID564287	Antimalarial activity against Plasmodium falciparum FCM29 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID237222	Plasma half life period after intravenous administration ( 20 mg/kg )	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID158369	In vitro antimalarial activity against Plasmodium falciparum FCR3	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether.
AID545371	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID564230	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID579482	Cytotoxicity against CHO cells by MTT assay	2011	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6	Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.
AID325366	Antiparasitic activity against Leishmania donovani in hamster assessed as reduction of liver parasite burden at 50 mg/kg, po	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID453386	Selectivity index, ratio of TC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum W2	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID1077199	Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID564306	Antimalarial activity against Plasmodium falciparum IMT Vol assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID403422	Antifungal activity against Candida albicans ATCC 90028 at 50 ug/mL by modified NCCLS method	2005	Journal of natural products, Aug, Volume: 68, Issue:8	Antifungal activity of artemisinin derivatives.
AID511254	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID563109	Antimalarial activity against Plasmodium falciparum IMT K4 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 S1034C, N1042D mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hr	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID361314	Induction of apoptosis in human HL60 cells assessed as mitochondrial membrane depolarization by flow cytometry	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID545377	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID279313	Inhibition of Plasmodium falciparum in HRP2 ELISA	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID674187	Growth inhibition of human OVCAR4 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID671462	Antimalarial activity against asexual erythrocyte stage of chloroquine-resistant Plasmodium falciparum Dd2 by parasite lactate dehydrogenase assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis, antimalarial activity and cytotoxicity of 10-aminoethylether derivatives of artemisinin.
AID755431	Cytotoxicity against human HepG2 cells after 72 hrs by formazan test	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID561062	Apparent oral clearance in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID545392	Half life in in adults with uncomplicated falciparum malaria at 32 to 35 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID151998	In vitro antimalarial activity against Plasmodium falciparum D6 (Sierra Leone)	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain.
AID576727	Antimalarial activity against Plasmodium falciparum D10 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID558847	Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID674172	Growth inhibition of human SNB78 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID449706	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID560762	Stability of compound in presence of methoxyhemoglobin assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Stability of peroxide antimalarials in the presence of human hemoglobin.
AID1239480	Resistance index, ratio of IC50 for human CEM/ADR5000 cells to IC50 for human CCRF-CEM cells	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID414407	Antimalarial activity after 48 hrs against chloroquine-sensitive Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Antitumour and antimalarial activity of artemisinin-acridine hybrids.
AID641623	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]-hypoxanthine incorporation	2011	Journal of natural products, Nov-28, Volume: 74, Issue:11	Cytotoxic and antimalarial azaphilones from Chaetomium longirostre.
AID1126746	Antibacterial activity against Staphylococcus aureus assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1186149	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 24 hrs by [3H]hypoxanthine incorporation assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID564296	Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID676620	Induction of apoptosis in human HL60 cells assessed as caspase 8 activation at 1 uM after 12 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1252950	Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID539292	Resistance index, ratio of IC50 for chloroquine-sensitive Plasmodium falciparum D10 to IC50 for chloroquine-resistant Plasmodium falciparum Dd2	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity.
AID158203	In vitro antimalarial activity against Plasmodium falciparum D6 Sierra Leone	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Antimalarial activity of new water-soluble dihydroartemisinin derivatives.
AID1239477	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID19482	Partition coefficient (logP)	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether.
AID361320	Induction of apoptosis in human HL60 cells assessed as activation of caspase 7 by Western blotting	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID561056	AUC in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID414405	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Antitumour and antimalarial activity of artemisinin-acridine hybrids.
AID361317	Induction of apoptosis in human HL60 cells assessed as increase in sub-G0/G1 population at 1 uM after 24 hrs by flow cytometry	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID561066	Antiplasmodial activity against Plasmodium falciparum K1	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID621890	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as [3H]-hypoxanthine uptake after 24 hrs by scintillation counting	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Diarylpropanes and an arylpropyl quinone from Combretum griffithii.
AID543633	Toxicity against Echinococcus multilocularis -infected in BALB/c mouse assessed as adverse effect	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID453400	Antibacterial activity against Staphylococcus aureus ATCC 29213 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID543627	Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 40 uM by trypan blue exclusion assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID674176	Growth inhibition of human HCT15 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID151997	In vitro antimalarial activity against Plasmodium falciparum W-2 Indochina	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain.
AID158019	In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum K1	1999	Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26	Novel, potent, semisynthetic antimalarial carba analogues of the first-generation 1,2,4-trioxane artemether.
AID676627	Induction of apoptosis in human HL60 cells assessed as caspase 9 activation after 1 to 3 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID323680	Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID564284	Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1126761	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1237 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID564301	Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564232	Antiplasmodial activity against Plasmodium falciparum clinical isolate after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID674193	Growth inhibition of human St-4 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID399045	Cytotoxicity against human KB cells by SRB assay	2005	Journal of natural products, Nov, Volume: 68, Issue:11	Hirsutane sesquiterpenes from the fungus Lentinus connatus BCC 8996.
AID399044	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 42 hrs by [3H]hypoxanthine uptake	2005	Journal of natural products, Nov, Volume: 68, Issue:11	Hirsutane sesquiterpenes from the fungus Lentinus connatus BCC 8996.
AID677000	Antiplasmodial activity against Plasmodium falciparum NF54 assessed as reduction in stage IV and V gametocyte formation at IC50 level incubated for 48 hrs measured 7 days post compound wash by Giemsa staining	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID425024	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Biomimetic transformation and biological activities of Globiferin, a terpenoid benzoquinone from Cordia globifera.
AID674184	Growth inhibition of human DMS114 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID564316	Antimalarial activity against Plasmodium falciparum IMT A4 harboring Ppcrt M74I, N75E, K76T, A220H, Q271E, N326S and I356T mutant gene, Pmdr1 Y184F, N1042D, D1246Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation co	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545378	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring parental pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID445035	Blood clearance in Sprague-Dawley rat at 2.5 to 3.5 mg/kg, iv	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID558838	Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID361322	Induction of apoptosis in human HL60 cells assessed as pyknotic nuclear fragments at 10 uM after 24 hrs in presence of Z-VAD-fmk	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID403421	Antifungal activity against Cryptococcus neoformans ATCC 90113 by modified NCCLS method	2005	Journal of natural products, Aug, Volume: 68, Issue:8	Antifungal activity of artemisinin derivatives.
AID539289	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity.
AID641578	Antimalarial activity against chloroquine-, mefloquine-, pyrimethamine-,atovaquone-resistant ring stage Plasmodium falciparum TM90-C2B infected in human A positive erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.
AID1126751	Antibacterial activity against Staphylococcus aureus assessed as zone of inhibition at 2 ug/ml	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID560760	Stability of compound in presence water assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Stability of peroxide antimalarials in the presence of human hemoglobin.
AID1126760	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 930 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID674178	Growth inhibition of human NCI-H23 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID760423	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for erythrocytic stage of chloroquine-resistant Plasmodium falciparum IndoChina W2	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine.
AID674192	Growth inhibition of human ACHN cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID564291	Antimalarial activity against Plasmodium falciparum 106/1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID414403	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Antitumour and antimalarial activity of artemisinin-acridine hybrids.
AID755432	Antiviral activity against Bovine viral diarrhea virus Oregon C24V genotype 1 subgenotype b infected in bovine EBTr cells assesed as inhibition of virus-induced cytopathic effect at 50 uM after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID444496	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxoartemisinin.
AID558829	Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID674195	Growth inhibition of human MKN7 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID563106	Antimalarial activity against Plasmodium falciparum IMT 16332 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E mutant gene, Pmdr1 N86Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID576507	Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID545376	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID563103	Antimalarial activity against Plasmodium falciparum IMT 10336 harboring Pfcrt Q271E mutant gene and Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID641577	Antimalarial activity against chloroquine-, pyrimethamine-resistant ring stage Plasmodium falciparum W2 infected in human A positive erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.
AID25398	Half life was determined	1998	Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9	Stability of acetal and non acetal-type analogs of artemisinin in simulated stomach acid.
AID563112	Antimalarial activity against Plasmodium falciparum 3D7 harboring Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1126758	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 760 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID674203	Growth inhibition of human PC3 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID748940	Half life in human	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID520094	Induction of heme alkylation of Fe(II) heme assessed as adduct A472 absorbance change at completion of reaction at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID563110	Antimalarial activity against Plasmodium falciparum IMT L1 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillatio	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID561054	Tmax in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID383954	Cytotoxicity against human KB cells by colorimetric method	2008	Journal of natural products, May, Volume: 71, Issue:5	Aurocitrin and related polyketide metabolites from the wood-decay fungus Hypocrea sp. BCC 14122.
AID1212147	Induction of CYP3A4 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID576728	Antimalarial activity against Plasmodium falciparum D10 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID383806	Cytotoxicity against mouse Ehrlich Ascites carcinoma by trypan blue exclusion assay	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Bioactive peroxides as potential therapeutic agents.
AID674179	Growth inhibition of human NCI-H226 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID543630	Antimicrobial activity against Echinococcus multilocularis metacestode assessed as increase in alkaline phosphatase activity at 10 uM	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID545363	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C3 harboring Dd2 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID158685	In vitro inhibitory activity against Plasmodium falciparum (sierra leone clone)	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID279314	Inhibition of Plasmodium falciparum AZ10011003 isolate in HRP2 ELISA	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID545361	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID576729	Antimalarial activity against Plasmodium falciparum D10 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID561063	Apparent volume of distribution in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID323682	Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID558834	Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID755429	Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1160927	Antimalarial activity against multi-drug-resistant Plasmodium falciparum W2 infected in human type A+ erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I assay	2014	Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21	Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID361319	Induction of apoptosis in human HL60 cells assessed as activation of caspase 3 by Western blotting	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID760425	Antiplasmodial activity against erythrocytic stage of multidrug-resistant Plasmodium falciparum Thailand K1 infected in human A positive RBC after 48 hrs by [3H]hypoxanthine incorporation assay	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine.
AID469264	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 assessed as [G-3H]hypoxanthine uptake after 24 hrs by scintillation counting	2009	Journal of natural products, Oct, Volume: 72, Issue:10	Cytotoxic and antiplasmodial compounds from the roots of Strophioblachia fimbricalyx.
AID755430	Cytotoxicity against human LS 174T cells after 72 hrs by formazan test	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1212138	Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID564295	Antimalarial activity against Plasmodium falciparum IMT 31 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID158863	Intrinsic equimolar activity against Plasmodium falciparum W2 Indochina relative to QHS	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID594705	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction.
AID361318	Induction of apoptosis in human HL60 cells assessed as increase in sub-G0/G1 population by flow cytometry	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID564231	Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum 3D7 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID576714	Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID477969	Antimalarial activity against Plasmodium falciparum K1 assessed as [G-3H]hypoxanthine uptake after 24 hrs by scintillation counting	2010	Journal of natural products, Apr-23, Volume: 73, Issue:4	Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID383952	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope technique	2008	Journal of natural products, May, Volume: 71, Issue:5	Aurocitrin and related polyketide metabolites from the wood-decay fungus Hypocrea sp. BCC 14122.
AID1239481	Antiviral activity against Human cytomegalovirus AD169 expressing GFP infected in HFF assessed as inhibition of viral replication after 7 days	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID755416	Antiviral activity against Bovine viral diarrhea virus Oregon C24V genotype 1 subgenotype b assessed as reduction in viral RNA release at 50 uM by RT-PCR analysis	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID564308	Antimalarial activity against Plasmodium falciparum D6 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID576716	Antimalarial activity against Plasmodium falciparum 7G8 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1212159	Induction of MRP1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID676637	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay in absence of DFOM	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID579483	Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive Plasmodium falciparum D10	2011	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6	Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.
AID674202	Growth inhibition of human DU145 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1252951	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID579481	Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive Plasmodium falciparum D10	2011	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6	Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.
AID1057261	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite growth inhibition after 48 hrs by SYBR green-1 dye-based fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID676651	Growth inhibition of human HBC5 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID562110	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID564286	Antimalarial activity against Plasmodium falciparum D6 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1252952	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID564314	Antimalarial activity against Plasmodium falciparum IMT Bres harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID283675	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1	2007	Journal of natural products, Apr, Volume: 70, Issue:4	A xanthocillin-like alkaloid from the insect pathogenic fungus Cordyceps brunnearubra BCC 1395.
AID674183	Growth inhibition of human DMS273 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID543634	Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 40 uM upto 2 days by trypan blue exclusion assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID760424	Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue assay	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine.
AID403420	Antifungal activity against Candida albicans ATCC 90028 by modified NCCLS method	2005	Journal of natural products, Aug, Volume: 68, Issue:8	Antifungal activity of artemisinin derivatives.
AID676649	Growth inhibition of human HBC4 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID362771	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1	2008	Journal of natural products, Sep, Volume: 71, Issue:9	11-Hydroxymonocerin from the plant endophytic fungus Exserohilum rostratum.
AID564289	Antimalarial activity against Plasmodium falciparum PA assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID671461	Antimalarial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum D10 by parasite lactate dehydrogenase assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis, antimalarial activity and cytotoxicity of 10-aminoethylether derivatives of artemisinin.
AID1186147	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID361303	Cytotoxicity against human PBMC after 72 hrs by MTT assay	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID1227982	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as reduction in parasite growth incubated for 24 hrs by [3H]hypoxanthine incorporation based microculture radioisotope technique based method	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Eremophilane Sesquiterpenes and Diphenyl Thioethers from the Soil Fungus Penicillium copticola PSU-RSPG138.
AID361321	Induction of apoptosis in human HL60 cells assessed as pyknotic nuclear fragments at 10 uM after 24 hrs	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID1212134	Inhibition of recombinant CYP2B6 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 10 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID520093	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID453385	Antiplasmodial activity against Plasmodium falciparum W2 infected in RBCs by parasitic LDH release assay	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID674166	Growth inhibition of human MDA-MB-231 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID676639	Ratio of IC50 for human HL60 cells in presence of DFOM to IC50 for human HL60 cells in absence of DFOM	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID361323	Reversal of induction of apoptosis in human HL60 cells assessed as inhibition of caspase 3 activation at 1 uM after 24 hrs by Western blotting in presence of Z-VAD-fmk	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID674180	Growth inhibition of human NCI-H522 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID543635	Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 40 uM after 6 days by trypan blue exclusion assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID470173	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 assessed as [3H]hypoxanthine incorporation after 24 hrs by microtiter plate scintillation counting	2009	Journal of natural products, Nov, Volume: 72, Issue:11	Diterpenes, sesquiterpenes, and a sesquiterpene-coumarin conjugate from Jatropha integerrima.
AID539291	Cytotoxicity against CHO cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity.
AID564294	Antimalarial activity against Plasmodium falciparum IMT A4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID449705	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID564305	Antimalarial activity against Plasmodium falciparum IMT L1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID361304	Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID428021	Induction of apoptosis in human HL60 cells assessed as occurrence of nuclear shrinkage, blebbing and apoptotic bodies at 2 uM after 24 hrs by acridine orange and ethidium bromide staining	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID368230	Anticancer activity against human HL60 cells by MTT assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells.
AID445034	Plasma clearance in Sprague-Dawley rat at 2.5 to 3.5 mg/kg, iv	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID333675	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 24 hrs by [3H]hypoxanthine uptake	2004	Journal of natural products, Nov, Volume: 67, Issue:11	10-membered macrolides from the insect pathogenic fungus Cordyceps militaris BCC 2816.
AID325363	Antiparasitic activity against Leishmania donovani in hamster assessed as reduction of spleen parasite burden at 25 mg/kg, po	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID453383	Antiplasmodial activity against Plasmodium falciparum D6 infected in RBCs by parasitic LDH release assay	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID1126750	Antibacterial activity against Pseudomonas aeruginosa assessed as zone of inhibition at 2 ug/ml	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID594699	Cytotoxicity against human HeLa cells after 7 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction.
AID563107	Antimalarial activity against Plasmodium falciparum IMT K14 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 Y184F, S1034C, N1042D, D1246Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxant	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1212144	Induction of CYP3A4 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID545373	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum C2 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID576720	Antimalarial activity against Plasmodium falciparum 7G8 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID558830	Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID539293	Selectivity index, ratio of IC50 for CHO cells to IC50 of chloroquine-sensitive Plasmodium falciparum D10	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity.
AID511251	Antimicrobial activity against Plasmodium falciparum by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID425948	Antimalarial activity as parasitaemia nadir after 24 hrs against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal single dose 64 hrs post infection	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Pharmacodynamics of doxycycline in a murine malaria model.
AID676608	Growth restoration activity in cdc2-1 rad9-deficient Saccharomyces cerevisiae assessed as growth zone at 400 ug/disc	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID511252	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID576718	Antimalarial activity against Plasmodium falciparum 7G8 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1186145	Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID236290	Volume distribution after intravenous administration of 20 mg/kg	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID279316	Inhibition of Plasmodium falciparum AZ10011017 isolate in HRP2 ELISA	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID674181	Growth inhibition of human NCI-H460 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID545365	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID287083	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by micro culture radioisotope technique	2007	Journal of natural products, May, Volume: 70, Issue:5	Bioactive compounds from Bauhinia purpurea possessing antimalarial, antimycobacterial, antifungal, anti-inflammatory, and cytotoxic activities.
AID1212137	Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID543637	Antimicrobial activity against Echinococcus granulosus metacestode assessed as loss of multicellular structure of germinal layer by transmission electron microscopy	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1057249	Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID236183	Plasma clearance after intravenous administration of 20 mg/kg	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID453401	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID576717	Antimalarial activity against Plasmodium falciparum 7G8 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID576723	Antimalarial activity against Plasmodium falciparum D10 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID158873	In vitro antimalarial activity against Plasmodium falciparum	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Mechanism-based development of new antimalarials: synthesis of derivatives of artemisinin attached to iron chelators.
AID449704	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID100410	Antileishmanial activity of compound against leishmania donovani was determined in luciferase assay	2003	Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20	Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria.
AID549354	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID774658	Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Approaches to protozoan drug discovery: phenotypic screening.
AID674168	Growth inhibition of human SF268 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID545359	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum TM6 infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1160928	Antimalarial activity against multi-drug-resistant Plasmodium falciparum TM90-C2B infected in human type A+ erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I assay	2014	Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21	Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID676626	Induction of apoptosis in human HL60 cells assessed as caspase 8 activation after 1 to 3 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1212149	Induction of CYP1A2 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID606571	Antimalarial activity against chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B infected in human A positive erythrocytes after 72 hrs by SYBR Green I assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.
AID1191134	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID755417	Acute toxicity in bovine EBTr cells infected with BVDV assessed as reduction in cell viability at 50 uM after 72 hrs	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID545374	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C3 harboring Dd2 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID399048	Cytotoxicity against african green monkey Vero cells by SRB assay	2005	Journal of natural products, Nov, Volume: 68, Issue:11	Hirsutane sesquiterpenes from the fungus Lentinus connatus BCC 8996.
AID576722	Antimalarial activity against Plasmodium falciparum 7G8 clone M4 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID576712	Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID563102	Antimalarial activity against Plasmodium falciparum IMT 9881 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1077196	Cytotoxicity against CHO cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1186148	Cytotoxicity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by XTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID558827	Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID674185	Growth inhibition of human LOXIMVI cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID474052	Antitumor activity against human HL60 cells after 72 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines.
AID564309	Antimalarial activity against Plasmodium falciparum FCM29 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1212155	Induction of CYP2E1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID414406	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Antitumour and antimalarial activity of artemisinin-acridine hybrids.
AID452991	Half life in Sprague-Dawley rat at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID453397	Antifungal activity against Candida krusei ATCC 6258 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID453404	Antibacterial activity against Mycobacterium intracellular ATCC 23068 by Franzblau method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID558831	Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564298	Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID325365	Antiparasitic activity against Leishmania donovani in hamster assessed as reduction of liver parasite burden at 25 mg/kg, po	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID558841	Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558835	Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID545370	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum TM6 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1252955	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID1126753	Antibacterial activity against duck Escherichia coli assessed as zone of inhibition at 2 ug/ml	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID676998	Selectivity index, ratio of CC50 for human HeLa cells to IC50 for VSV-G pseudotyped HIV1 lentiviral particles	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID563104	Antimalarial activity against Plasmodium falciparum IMT 10354 harboring Ppcrt M74I, N75E, K76T, A220S mutant gene, Pmdr1 D1246Y mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1057250	Cytotoxicity against human HT29-AK cells assessed as cell viability after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1212146	Induction of CYP2B6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID676997	Selectivity index, ratio of CC50 for human HeLa cells to IC50 for Plasmodium falciparum Dd2 ring stage cells	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID674194	Growth inhibition of human MKN1 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID561058	AUC (0 to infinity) in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID579479	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 by lactate dehydrogenase assay	2011	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6	Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.
AID545366	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID676621	Induction of apoptosis in human HL60 cells assessed as caspase 9 activation at 1 uM after 12 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID399046	Cytotoxicity against human BC cells by SRB assay	2005	Journal of natural products, Nov, Volume: 68, Issue:11	Hirsutane sesquiterpenes from the fungus Lentinus connatus BCC 8996.
AID383956	Cytotoxicity against human NCI-H187 cells by colorimetric method	2008	Journal of natural products, May, Volume: 71, Issue:5	Aurocitrin and related polyketide metabolites from the wood-decay fungus Hypocrea sp. BCC 14122.
AID674173	Growth inhibition of human HCC2998 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID558837	Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID452994	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID674171	Growth inhibition of human SNB75 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1077197	Resistance index, ratio of IC50 for asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID564236	Antiplasmodial activity against Plasmodium falciparum harboring wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID428025	Induction of apoptosis in human HL60 cells assessed as DNA fragmentation at 4 uM after 24 hrs using ethidium bromide staining by DNA gel electrophoresis	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID566771	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope technique	2010	Journal of natural products, Dec-27, Volume: 73, Issue:12	Pyridone and tetramic acid alkaloids from the spider pathogenic fungus Torrubiella sp. BCC 2165.
AID664753	Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hrs prior to hypoxanthine addition measured after 18 hrs by liquid scintillation counting	2012	Journal of natural products, Apr-27, Volume: 75, Issue:4	Bifunctionalized amphilectane diterpenes from the sponge Stylissa cf. massa.
AID159028	Antimalarial activity against chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum W2	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies.
AID428115	Antiparasitic activity as parasitaemia against Plasmodium berghei ANKA infected Swiss mice (Mus musculus) at 30 mg/kg intraperitoneal dose 64 hrs post infection	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
AID676993	Antiplasmodial activity against drug resistant Plasmodium falciparum Dd2 ring stage cells assessed as reduction parasitemia by Malstat assay	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID545368	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring D10 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID674191	Growth inhibition of human RXF631L cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID676619	Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activation at 1 uM after 12 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID453403	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID383955	Cytotoxicity against human BC cells by colorimetric method	2008	Journal of natural products, May, Volume: 71, Issue:5	Aurocitrin and related polyketide metabolites from the wood-decay fungus Hypocrea sp. BCC 14122.
AID543632	Antimicrobial activity against Echinococcus multilocularis -infected in BALB/c mouse assessed as parasite weight at 200 mg/kg body weight intragastrically administered 8 weeks post-infecion (Rvb = 5.71+/-1.79 g)	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1212153	Induction of CYP3A5 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID1335799	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected human erythrocytes assessed as reduction in parasite viability after 24 hrs by [3H]-hypoxanthine incorporation assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors.
AID560761	Stability of compound in presence of oxyhemoglobin assessed as pseudo-first order degradation rate constant at 10 uM at 20degC over 24 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Stability of peroxide antimalarials in the presence of human hemoglobin.
AID453395	Antifungal activity against Candida albicans ATCC 90028 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID453398	Antifungal activity against Cryptococcus neoformans ATCC 90113 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID674175	Growth inhibition of human HT-29 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID674170	Growth inhibition of human SF539 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID674167	Growth inhibition of human U251 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID676609	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID262123	Antiangiogenic activity at chorioallantoic membrane of chick embryo at 5 nmol per egg	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane.
AID323683	Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID1186150	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 4 days by green fluorescent protein detection method	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents.
AID325356	Growth inhibition of Trypanosoma brucei rhodesiense trypomastigotes after 72 hrs by Alamar blue assay	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID676650	Growth inhibition of human BSY1 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID774663	Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Approaches to protozoan drug discovery: phenotypic screening.
AID279317	Inhibition of Plasmodium falciparum AZ10011022 isolate in HRP2 ELISA	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID1057256	Induction of apoptosis in human HL60 cells assessed as activation of caspase-3 activity at 0.2 to 0.6 uM after 24 hrs by flow cytometric analysis	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID427228	Antimalarial activity against Plasmodium falciparum K1 by microculture radioisotope technique	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Isocoumarin glucosides from the scale insect fungus Torrubiella tenuis BCC 12732.
AID561060	Half life in Plasmodium falciparum-infected patient at 40 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID674189	Growth inhibition of human OVCAR8 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID564235	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID558833	Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID158018	In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3	1999	Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26	Novel, potent, semisynthetic antimalarial carba analogues of the first-generation 1,2,4-trioxane artemether.
AID378813	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake	2006	Journal of natural products, Oct, Volume: 69, Issue:10	Bioactive compounds from the seed fungus Menisporopsis theobromae BCC 3975.
AID453387	Toxicity against african green monkey Vero cells	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID158855	Inhibitory concentration against Plasmodium falciparum D6 (Sierra Leone)	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID545364	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C6harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID449703	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID576715	Antimalarial activity against Plasmodium falciparum 7G8 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID452993	Blood clearance in Sprague-Dawley rat at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID674190	Growth inhibition of human SKOV3 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID545367	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum 7G8 harboring parental pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID674188	Growth inhibition of human OVCAR5 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID558845	Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID444022	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents.
AID760426	Antiplasmodial activity against erythrocytic stage of chloroquine-resistant Plasmodium falciparum IndoChina W2 infected in human A positive RBC after 48 hrs by [3H]hypoxanthine incorporation assay	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine.
AID564304	Antimalarial activity against Plasmodium falciparum IMT K4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID545369	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1126755	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 741 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1244907	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID564310	Antimalarial activity against Plasmodium falciparum FCR3 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID158646	In vitro antimalarial activity against Plasmodium berghei	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin.
AID564318	Antimalarial activity against Plasmodium falciparum IMT 8425 harboring Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID158862	Intrinsic equimolar activity against Plasmodium falciparum D6 (Sierra Leone) relative to QHS	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID325355	Growth inhibition of Trypanosoma cruzi epimastigotes after 72 hrs by Alamar blue assay	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID1252954	Cytotoxicity against African green monkey Vero cells after 4 days by GFP detection method	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies.
AID594702	Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive Plasmodium falciparum D10	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction.
AID428017	Inhibition of human HL60 cell proliferation after 72 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID1177057	Antiprotozoan activity against Plasmodium falciparum infected in mouse assessed as reduction in parasite growth at 50 mg/kg, ip QD for 4 days	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID323679	Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID761652	Antimalarial activity against Plasmodium falciparum K1 assessed as reduction in parasite growth measuring [3H]-hypoxanthine uptake by microculture radioisotope technique	2013	Journal of natural products, Jul-26, Volume: 76, Issue:7	Antiplasmodial and cytotoxic flavans and diarylpropanes from the stems of Combretum griffithii.
AID564297	Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID676992	Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage cells assessed as reduction parasitemia by Malstat assay	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID1126757	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 758 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID323678	Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID144637	Evaluated for the neurotoxicity against NB2a Neuroblastoma cells.	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID674165	Growth inhibition of human MCF7 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID1077195	Selectivity index, ratio of IC50 for CHO cells to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID564311	Antimalarial activity against Plasmodium falciparum PA harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID428023	Cell cycle arrest in human HL60 cells assessed as accumulation at subG1 phase at 4 uM after 24 hrs using propidium iodide staining by flow cytometry	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID1212145	Induction of CYP2C9 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID131169	Compound was tested in vivo for antimalarial activity against Plasmodium berghei in the mice (Mus musculus) model.	1999	Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26	Novel, potent, semisynthetic antimalarial carba analogues of the first-generation 1,2,4-trioxane artemether.
AID676994	Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID564317	Antimalarial activity against Plasmodium falciparum IMT 31 harboring Ppcrt I371R mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1077198	Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID543631	Antimicrobial activity against Echinococcus multilocularis metacestode assessed as loss of multicellular structure of germinal layer by transmission electron microscopy	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID444495	Anticancer activity against human XF498 cells by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxoartemisinin.
AID606570	Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 infected in human A positive erythrocytes after 72 hrs by SYBR Green I assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.
AID579480	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 by lactate dehydrogenase assay	2011	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6	Synthesis, in vitro antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids.
AID377621	Antimalarial activity after 42 hrs against Plasmodium falciparum K1	2006	Journal of natural products, Jun, Volume: 69, Issue:6	Chromone derivatives from the filamentous fungus Lachnum sp. BCC 2424.
AID564315	Antimalarial activity against Plasmodium falciparum IMT Guy harboring Ppcrt K76T, A220S, N326D and I371R mutant gene, Pmdr1 T184FN, 1042D and D1246Y, mutant gene and Pfmrp H191Y and S437A mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as in	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1126763	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1259 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID558839	Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID561067	Antiplasmodial activity against Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation by beta counting	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID1126745	Antibacterial activity against Pseudomonas aeruginosa assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID576721	Antimalarial activity against Plasmodium falciparum 7G8 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1244908	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID674174	Growth inhibition of human KM12 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID425946	Toxicity in Plasmodium berghei ANKA infected Swiss mice (Mus musculus) assessed as median time for adverse effect at 30 mg/kg, intraperitoneally administered as single dose 64 hrs after infection measured after 24 hrs	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Pharmacodynamics of doxycycline in a murine malaria model.
AID564292	Antimalarial activity against Plasmodium falciparum IMT Bres assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564313	Antimalarial activity against Plasmodium falciparum 106/1 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S and I356T mutant gene, Pmdr1 N86Y mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID361302	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID563108	Antimalarial activity against Plasmodium falciparum IMT K2 harboring Ppcrt M74I, N75E, K76T, A220S, Q271E, N326S mutant gene, Pmdr1 S1034C, N1042D mutant gene and Pfmrp H191Y and S437A mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hr	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID444498	Anticancer activity against human SKOV3 cells by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxoartemisinin.
AID504298	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope technique	2010	Journal of natural products, Sep-24, Volume: 73, Issue:9	Anthraquinone, cyclopentanone, and naphthoquinone derivatives from the sea fan-derived fungi Fusarium spp. PSU-F14 and PSU-F135.
AID545372	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID1244912	Selectivity ratio of IC50 for human HL7702 cells to IC50 for human SMMC7721 cells	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID311493	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope assay	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Cassane furanoditerpenoids from the seed kernels of Caesalpinia bonduc from Thailand.
AID399047	Cytotoxicity against human NCI-H187 cells by SRB assay	2005	Journal of natural products, Nov, Volume: 68, Issue:11	Hirsutane sesquiterpenes from the fungus Lentinus connatus BCC 8996.
AID1244910	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID1212117	Induction of MRP2 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID511255	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID520092	Induction of heme alkylation of Fe(II) heme assessed as loss of heme at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID1126756	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 753 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1212156	Induction of UGT1A9 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID1126764	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1288 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID543628	Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 10 uM by trypan blue exclusion assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID383957	Cytotoxicity against african green monkey Vero cells by colorimetric method	2008	Journal of natural products, May, Volume: 71, Issue:5	Aurocitrin and related polyketide metabolites from the wood-decay fungus Hypocrea sp. BCC 14122.
AID563105	Antimalarial activity against Plasmodium falciparum IMT 10500 harboring Pfcrt Q271E mutant gene and Ppcrt I371R mutant gene and Pfnhe-1 ms4760 microsatellite mutant assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID674182	Growth inhibition of human A549 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID452992	Volume of distribution in Sprague-Dawley rat at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID676625	Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activation after 1 to 3 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID558842	Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID755412	Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability at 1 uM measured on day 21 by natural Red test	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID561068	Antiplasmodial activity against Plasmodium falciparum D6 isolated from po dosed patient with malaria	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID558826	Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID444500	Anticancer activity against human HCT15 cells by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Synthesis and anticancer activity of novel amide derivatives of non-acetal deoxoartemisinin.
AID158215	In vitro antimalarial activity against Plasmodium falciparum W-2 (Indochina)	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Antimalarial activity of new water-soluble dihydroartemisinin derivatives.
AID564303	Antimalarial activity against Plasmodium falciparum IMT K2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564285	Antimalarial activity against Plasmodium falciparum W2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID674198	Growth inhibition of human MKN74 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID576725	Antimalarial activity against Plasmodium falciparum D10 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID558844	Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1126749	Antibacterial activity against Salmonella assessed as zone of inhibition at 2 ug/ml	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID361301	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID1762667	Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced nitric oxide production incubated for 24 hrs by 2, 3-diaminonaphthalene based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID478101	Antimalarial activity against Plasmodium falciparum K1 after 24 hrs by [G-3H]hypoxanthine uptake assay	2010	Journal of natural products, Apr-23, Volume: 73, Issue:4	Hopane-type triterpenes and binaphthopyrones from the scale insect pathogenic fungus Aschersonia paraphysata BCC 11964.
AID428018	Cytotoxicity against human HL60 cells after 72 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID1239478	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID453396	Antifungal activity against Candida glabrata ATCC 90030 by modified CLSI/NCCLS method	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID453384	Selectivity index, ratio of TC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum D6	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.
AID772516	Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Using genetic methods to define the targets of compounds with antimalarial activity.
AID511253	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID545375	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum C6harboring 7G8 pfcrt allele infected in erythrocytes assessed as [3H]hypoxanthine incorporation in presence of piperaquine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
AID674196	Growth inhibition of human MKN28 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID564312	Antimalarial activity against Plasmodium falciparum HB3 harboring Ppcrt I371R mutant gene and Pfmdr1 Y184F mutant gene assessed as incorporation of [3]H hypoxanthine after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1182043	Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 assessed as reduction in parasite growth by [3H]-hypoxanthine uptake assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	Triterpene lactones from cultures of Ganoderma sp. KM01.
AID361325	Reversal of induction of apoptosis in human HL60 cells assessed as formation of sub-G0/G1 population at 10 uM after 24 hrs by flow cytometry in presence of Z-VAD-fmk	2007	The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13	Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.
AID423418	Antiplasmodial activity after 24 hrs against Plasmodium falciparum K1 by [G-3H]hypoxanthine uptake	2009	Journal of natural products, Apr, Volume: 72, Issue:4	Isariotins E and F, spirocyclic and bicyclic hemiacetals from the entomopathogenic fungus Isaria tenuipes BCC 12625.
AID1212150	Induction of CYP2A6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID539290	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Artemisinin-quinoline hybrid-dimers: synthesis and in vitro antiplasmodial activity.
AID1244909	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation.
AID676996	Cytotoxicity against human HeLa cells by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID594704	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction.
AID325357	Growth inhibition of Leishmania donovani promastigotes after 72 hrs by Alamar blue assay	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
AID1212151	Induction of CYP2C8 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID564300	Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID671464	Resistance index ratio of IC50 for asexual erythrocyte stage of chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum D10	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis, antimalarial activity and cytotoxicity of 10-aminoethylether derivatives of artemisinin.
AID772517	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Using genetic methods to define the targets of compounds with antimalarial activity.
AID1212148	Induction of CYP2C9 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
AID561069	Antiplasmodial activity against Plasmodium falciparum K1 isolated from po dosed patient with malaria	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
AID674177	Growth inhibition of human HCT116 cells	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
AID719099	Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Facile synthesis and anticancer activity of C-10 non-acetal deoxoartemisinin dimers.
AID604714	Antimalarial activity against multidrug-resistance Plasmodium falciparum K1 assessed as growth inhibition by microdilution radioisotope technique	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Kabiramides J and K, trisoxazole macrolides from the sponge Pachastrissa nux.
AID1191136	Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum W2 to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID1191137	Cytotoxicity against human WI38 cells assessed as inhibition of proliferation after 24 hrs by SRB assay	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID576713	Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID563687	Antimalarial activity against Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs by [3H]hypoxanthin incorporation assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID444930	Half life in Sprague-Dawley rat at 2.5 to 3.5 mg/kg, iv	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID774661	Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Approaches to protozoan drug discovery: phenotypic screening.
AID1126752	Antibacterial activity against Escherichia coli assessed as zone of inhibition at 2 ug/ml	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID428026	Growth inhibition of mouse P388 cells after 72 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
AID563688	Antimalarial activity against Plasmodium falciparum assessed as resistant isolates	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID564293	Antimalarial activity against Plasmodium falciparum IMT Guy assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID383712	Antimalarial activity against Plasmodium falciparum K1 by microculture radioisotope assay	2008	Journal of natural products, May, Volume: 71, Issue:5	Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
AID576726	Antimalarial activity against Plasmodium falciparum D10 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID755422	Cytotoxicity against bovine EBTr cells at 20 to 100 uM after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID558832	Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	22 (1.51)	18.7374
1990's	87 (5.99)	18.2507
2000's	251 (17.27)	29.6817
2010's	744 (51.20)	24.3611
2020's	349 (24.02)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Trials	279 (19.66%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	9 (16.98%)	6.00%
Reviews	52 (3.66%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Case Studies	19 (1.34%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Observational	9 (0.63%)	0.25%
Other	7 (100.00%)	84.16%
Other	44 (83.02%)	84.16%
Other	1,060 (74.70%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (116)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children [NCT01231880]	Phase 3	740 participants (Actual)	Interventional	2011-02-28	Completed
An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of Dihydroartemisinin (DHA)-Piperaquine for Patients With Uncomplicated Malaria [NCT01280162]		222 participants (Actual)	Interventional	2010-09-30	Completed
Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup [NCT01288820]	Phase 3	331 participants (Actual)	Interventional	2011-01-31	Completed
Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial [NCT01231113]	Phase 3	417 participants (Actual)	Interventional	2011-07-31	Completed
Intermittent Preventive Treatment in Pregnancy With Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine to Prevent Malaria Infection and Reduce Adverse Pregnancy Outcomes in Papua New Guinea - a Randomised Controlled Trial [NCT05426434]	Phase 3	1,172 participants (Anticipated)	Interventional	2022-08-31	Recruiting
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL) [NCT05555862]	Phase 2	48 participants (Anticipated)	Interventional	2023-02-10	Recruiting
An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparu [NCT02461186]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-06-30	Withdrawn(stopped due to Change of the study site due to the current political climate in Myanmar.)
Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites [NCT03697668]	Phase 2	50 participants (Anticipated)	Interventional	2017-09-17	Recruiting
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants [NCT02793622]	Phase 3	782 participants (Actual)	Interventional	2016-09-30	Completed
Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria [NCT02110784]	Phase 2	27 participants (Actual)	Interventional	2014-06-18	Terminated(stopped due to Low recruitment)
Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam [NCT01165372]	Phase 2	166 participants (Actual)	Interventional	2010-08-31	Completed
Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia [NCT04189744]	Phase 3	5,436 participants (Actual)	Interventional	2019-12-15	Completed
Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes [NCT02325180]	Phase 4	338 participants (Actual)	Interventional	2015-01-31	Completed
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua [NCT06036030]	Phase 2	50 participants (Actual)	Interventional	2019-01-11	Completed
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA) [NCT04844099]	Phase 3	723 participants (Actual)	Interventional	2021-04-09	Completed
Observational Study to Evaluate the Clinical Safety After Introduction of the Fixed Dose Artemisinin-based Combination Therapy Eurartesim® (Dihydroartemisinin/Piperaquine [Dha/Pqp]) in Public Health Districts in Sub-Saharan Africa. [NCT02199951]		10,000 participants (Anticipated)	Observational	2013-09-30	Recruiting
Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly as Intermittent Preventive Treatment in School-aged Children in Burkina Faso [NCT05946642]	Phase 3	13,000 participants (Anticipated)	Interventional	2023-07-15	Recruiting
A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos [NCT02802813]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2016-06-14	Completed
DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy [NCT04487145]	Phase 4	190 participants (Actual)	Interventional	2020-11-23	Completed
The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians [NCT02434952]	Phase 4	109 participants (Actual)	Interventional	2014-10-31	Completed
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A [NCT03640403]	Phase 3	1,555 participants (Actual)	Interventional	2019-03-26	Active, not recruiting
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of Dihydroartemisinin Tablets in Patients With Systemic Lupus Erythematosus [NCT03396393]	Phase 2	120 participants (Anticipated)	Interventional	2018-03-31	Not yet recruiting
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda [NCT04336189]	Phase 3	2,757 participants (Anticipated)	Interventional	2020-12-28	Recruiting
Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland [NCT02315690]	Phase 3	4,000 participants (Actual)	Interventional	2015-09-30	Completed
Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects [NCT02324738]	Phase 4	16 participants (Actual)	Interventional	2015-01-31	Completed
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL) [NCT06075264]	Phase 2	27 participants (Anticipated)	Interventional	2023-12-06	Recruiting
Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children With Uncomplicated Clinical Malaria in Rural Rwanda [NCT04767217]	Phase 4	528 participants (Anticipated)	Interventional	2021-06-14	Recruiting
A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission. [NCT02259426]	Phase 3	120 participants (Actual)	Interventional	2014-10-31	Completed
Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania [NCT03431714]	Phase 4	333 participants (Actual)	Interventional	2017-07-14	Completed
Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers [NCT01103830]	Phase 1	287 participants (Actual)	Interventional	2010-02-28	Completed
Comparison of the Electrocardiographic Effects in Relation to Pharmacokinetic Profile of Chloroquine and Piperaquine in Healthy Thai Subjects [NCT02192944]	Phase 4	16 participants (Actual)	Interventional	2014-07-31	Completed
Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months [NCT01082705]	Phase 3	323 participants (Actual)	Interventional	2010-04-30	Completed
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination [NCT03576313]	Phase 3	4,939 participants (Actual)	Interventional	2018-08-11	Completed
Evaluation of the Household-level Impact of a Single Round of Intermittent Preventive Treatment of Malaria in Schoolchildren: A Randomized Study [NCT04660110]	Phase 3	1,500 participants (Anticipated)	Interventional	2021-01-28	Recruiting
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children [NCT00393679]	Phase 3	4,112 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria [NCT00948896]	Phase 3	600 participants (Actual)	Interventional	2010-06-30	Completed
Effectiveness of Seasonal Malaria Chemoprevention in Koulikoro, Mali [NCT04149106]	Phase 3	4,556 participants (Anticipated)	Interventional	2019-07-01	Active, not recruiting
[NCT00845533]	Phase 4	0 participants	Interventional	2007-08-31	Completed
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens [NCT05980156]	Phase 4	646 participants (Actual)	Interventional	2023-02-13	Completed
[NCT00868465]		600 participants (Anticipated)	Interventional	2009-04-30	Completed
Open Label Randomized Study Evaluating the in Vivo Efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under Five Years of Age in Western Kenya [NCT05060198]		340 participants (Actual)	Interventional	2016-06-17	Completed
A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Di [NCT02184637]	Phase 1	120 participants (Actual)	Interventional	2014-07-31	Completed
The Evaluation of the Effect of Dihydroartemisinin in Patients With Polycystic Ovary Syndrome [NCT05465135]	Phase 4	20 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight [NCT04147546]	Phase 3	340 participants (Actual)	Interventional	2020-08-31	Completed
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi [NCT02721420]	Phase 3	375 participants (Anticipated)	Interventional	2016-03-24	Recruiting
Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial [NCT02721186]		22,500 participants (Actual)	Interventional	2016-04-30	Completed
A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam [NCT01887821]	Phase 4	330 participants (Actual)	Interventional	2013-02-28	Completed
A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar [NCT02792816]		550 participants (Actual)	Observational	2009-06-30	Completed
Chemoprevention With Monthly IPTp With Dihydroartemisinin-piperaquine for Malaria in HIV-infected Pregnant Participants on Daily Cotrimoxazole in Kenya and Malawi: a Multi-centre Placebo-controlled Trial [NCT04158713]	Phase 3	898 participants (Actual)	Interventional	2019-11-11	Completed
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia [NCT02654730]	Phase 2/Phase 3	61 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Enrollment took longer than anticipated; it was financially and logistically impossible to recruit the final cohort (G6PDd 0.4mg/kg PQ).)
Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations [NCT02653898]	Phase 4	1,050 participants (Actual)	Interventional	2016-01-31	Active, not recruiting
Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan [NCT00682578]	Phase 3	1,086 participants (Actual)	Interventional	2007-07-31	Completed
IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda [NCT00852371]	Phase 3	760 participants (Actual)	Interventional	2008-02-29	Completed
Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau [NCT04897919]	Phase 4	474 participants (Actual)	Interventional	2015-08-01	Completed
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial [NCT02671175]	Phase 3	1,049 participants (Actual)	Interventional	2016-05-20	Completed
Enhancing Immunity to Malaria in Young Children With Effective Chemoprevention [NCT04978272]	Phase 3	924 participants (Actual)	Interventional	2022-02-08	Active, not recruiting
A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Mal [NCT02612545]	Phase 1	216 participants (Actual)	Interventional	2015-11-20	Completed
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria [NCT00852423]	Phase 3	3,428 participants (Actual)	Interventional	2010-06-30	Completed
The Efficacy and Safety of Pyronaridine-artesunate Combined With Low Dose Primaquine for Preventing Transmission of P. Falciparum Gametocytes in Sub-Saharan Africa [NCT04049916]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2019-09-12	Completed
[NCT01075945]	Phase 4	140 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in the North Region of Cameroon [NCT05340153]	Phase 4	184 participants (Anticipated)	Interventional	2022-04-11	Not yet recruiting
Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission [NCT02605720]	Phase 3	78 participants (Actual)	Interventional	2015-09-30	Completed
In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure [NCT02590627]	Phase 4	509 participants (Actual)	Interventional	2014-05-31	Completed
Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial [NCT01878357]	Phase 4	1,488 participants (Actual)	Interventional	2013-06-30	Completed
Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania [NCT01930331]	Phase 4	60 participants (Actual)	Interventional	2014-01-07	Completed
Interactions Between HIV and Malaria in African Children [NCT00527800]	Phase 3	351 participants (Actual)	Interventional	2007-08-31	Completed
Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Mal [NCT01326754]		498 participants (Actual)	Interventional	2011-08-31	Completed
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) [NCT04609098]	Phase 2	80 participants (Actual)	Interventional	2020-10-29	Completed
Effectiveness of Dihydroartemisinin-piperaquine as Seasonal Malaria Chemoprophylaxis in Extended High Transmission Settings of Tanzania: an Open Cluster Randomized Clinical Trial. [NCT05874869]		13,800 participants (Actual)	Interventional	2020-07-01	Completed
A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria [NCT01992900]	Phase 2	300 participants (Actual)	Interventional	2013-11-30	Completed
Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial [NCT02001428]		757 participants (Actual)	Interventional	2014-07-21	Completed
'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial [NCT02009215]	Phase 4	10,746 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children Aged 1-5 Years in an Area of Seasonal Malaria Transmission in Upper River Division, The Gambia [NCT00561899]	Phase 2/Phase 3	1,295 participants (Actual)	Interventional	2007-08-31	Completed
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax [NCT01640574]	Phase 3	680 participants (Actual)	Interventional	2012-02-29	Completed
IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania [NCT03208179]	Phase 3	4,680 participants (Actual)	Interventional	2018-03-29	Completed
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria [NCT02614404]	Phase 1	15 participants (Actual)	Interventional	2015-11-30	Completed
Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission: a Cluster Randomized Trial [NCT02878200]		2,236 participants (Actual)	Interventional	2016-11-04	Completed
Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali [NCT02831023]	Phase 2	80 participants (Actual)	Interventional	2016-07-31	Completed
Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra [NCT01389557]	Phase 4	77 participants (Actual)	Interventional	2011-02-28	Completed
Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia [NCT01392014]	Phase 4	374 participants (Actual)	Interventional	2008-12-31	Completed
Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in Tanzania [NCT04245033]	Phase 4	4,100 participants (Actual)	Interventional	2020-07-20	Active, not recruiting
A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy [NCT01054248]	Phase 3	511 participants (Actual)	Interventional	2010-02-16	Completed
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia [NCT05829187]	Phase 2	36 participants (Actual)	Interventional	2022-11-01	Completed
Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia [NCT01872702]		8,000 participants (Actual)	Interventional	2013-04-30	Completed
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria? [NCT05788094]	Phase 4	388 participants (Anticipated)	Interventional	2023-06-26	Recruiting
Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique [NCT02914145]		240,502 participants (Actual)	Interventional	2015-11-30	Completed
Efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Siaya and Bungoma Counties, Kenya [NCT04767191]	Phase 4	400 participants (Actual)	Interventional	2021-03-15	Completed
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania [NCT02909712]	Phase 2	201 participants (Actual)	Interventional	2016-09-30	Completed
Evaluation of the Safety and Efficacy of Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment of Malaria in HIV-infected Pregnant Women [NCT03671109]	Phase 3	666 participants (Actual)	Interventional	2019-09-18	Completed
Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. [NCT01704508]	Phase 4	346 participants (Actual)	Interventional	2012-11-30	Completed
Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal [NCT00529620]	Phase 3	1,833 participants (Actual)	Interventional	2007-09-30	Completed
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial [NCT02940756]	Phase 4	1,615 participants (Actual)	Interventional	2017-03-15	Completed
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi [NCT06083688]	Phase 4	1,000 participants (Anticipated)	Interventional	2024-10-31	Not yet recruiting
Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon [NCT01845701]	Phase 3	720 participants (Actual)	Interventional	2010-03-31	Completed
An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana. [NCT01651416]	Phase 4	2,400 participants (Actual)	Interventional	2012-07-31	Completed
Evaluation of a Pilot Implementation of Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine to Prevent Adverse Birth Outcomes in Papua, Indonesia [NCT05294406]	Phase 4	1,420 participants (Anticipated)	Interventional	2022-02-07	Active, not recruiting
Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia [NCT01743820]	Phase 2	81 participants (Actual)	Interventional	2013-09-30	Completed
Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 [NCT01755559]	Phase 4	663 participants (Actual)	Interventional	2013-06-30	Completed
Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Rad [NCT02802501]	Phase 3	150 participants (Actual)	Interventional	2018-04-08	Completed
Evaluation of Community-based Screening and Treatment for Malaria in the KEMRI/CDC Health and Demographic Surveillance System (HDSS) in Western Kenya [NCT02987270]	Phase 3	90,000 participants (Actual)	Interventional	2013-04-30	Completed
Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial [NCT04844905]	Phase 3	24,000 participants (Anticipated)	Interventional	2021-05-03	Recruiting
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) [NCT04778813]	Phase 4	1,050 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]	Phase 3	300 participants (Actual)	Interventional	2013-01-31	Completed
Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM) [NCT01640587]		76 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to No adequate malaria patient)
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission [NCT05244954]	Phase 4	746 participants (Actual)	Interventional	2022-02-01	Completed
A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi [NCT03009526]	Phase 3	602 participants (Actual)	Interventional	2017-01-17	Completed
Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial [NCT04864444]		10,715 participants (Actual)	Interventional	2021-06-19	Completed
A Hybrid Effectiveness-implementation Study to Assess the Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Five Districts in Karamoja Region, Uganda [NCT05323721]	Phase 4	6,805 participants (Actual)	Interventional	2022-06-01	Active, not recruiting
Efficacy and Safety of Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum and Plasmodium Vivax Malaria in Timika, Indonesia [NCT02353494]		130 participants (Actual)	Observational	2015-03-31	Completed
Boosting the Impact of Seasonal Malaria Chemoprevention (SMC) Through Simultaneous Screening and Treatment of SMC-Children's Roommates in Burkina Faso [NCT04816461]	Phase 4	789 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) [NCT03178643]	Phase 4	246 participants (Actual)	Interventional	2018-01-23	Completed
Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya [NCT01899820]	Phase 3	2,100 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
Field Study of the Pharmacokinetics and Pharmacodynamics of Artemisinin-based Combination Therapy for Gametocyte Clearance and Post-treatment Chemoprotection in Zambian Children With Uncomplicated Falciparum Malaria [NCT04009343]	Phase 2/Phase 3	182 participants (Anticipated)	Interventional	2019-06-19	Active, not recruiting
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) [NCT02511353]	Phase 2	141 participants (Actual)	Interventional	2015-07-31	Completed
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1) [NCT02163447]	Phase 3	300 participants (Actual)	Interventional	2014-06-23	Completed
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2) [NCT02282293]	Phase 3	200 participants (Actual)	Interventional	2014-12-09	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00948896 (4) [back to overview]	Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants
NCT00948896 (4) [back to overview]	Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants
NCT02163447 (14) [back to overview]	Prevalence of Parasitemia in Infants
NCT02163447 (14) [back to overview]	Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy
NCT02163447 (14) [back to overview]	Prevalence of Gametocytemia in Pregnant Women
NCT02163447 (14) [back to overview]	Prevalence of Gametocytemia in Infants
NCT02163447 (14) [back to overview]	Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery
NCT02163447 (14) [back to overview]	Prevalence of Anemia in Pregnant Women
NCT02163447 (14) [back to overview]	Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery
NCT02163447 (14) [back to overview]	Incidence of Malaria in Pregnant Women
NCT02163447 (14) [back to overview]	Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]	Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]	Incidence of Hospital Admissions in Infants
NCT02163447 (14) [back to overview]	Incidence of Complicated Malaria in Infants
NCT02163447 (14) [back to overview]	Prevalence of Placental Malaria
NCT02163447 (14) [back to overview]	Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP
NCT02282293 (7) [back to overview]	Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)
NCT02282293 (7) [back to overview]	Incidence of Malaria, Pregnant Women
NCT02282293 (7) [back to overview]	Number of Monthly Routine Visits With Positive Blood Samples for Parasites
NCT02282293 (7) [back to overview]	Number of Participants With Placental Malaria
NCT02282293 (7) [back to overview]	Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia
NCT02282293 (7) [back to overview]	Maternal Parasitemia at Delivery by Microscopy and LAMP
NCT02282293 (7) [back to overview]	Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)
NCT02793622 (14) [back to overview]	Prevalence of Maternal Malaria
NCT02793622 (14) [back to overview]	Prevalence of Placental Malaria by Histology
NCT02793622 (14) [back to overview]	Prevalence of Placental Parasitemia
NCT02793622 (14) [back to overview]	Prevalence of Anemia in Infants
NCT02793622 (14) [back to overview]	Incidence of Complicated Malaria in Infants
NCT02793622 (14) [back to overview]	Incidence of Hospital Admissions in Infants
NCT02793622 (14) [back to overview]	Incidence of Malaria in Infants
NCT02793622 (14) [back to overview]	Infant Mortality Rate
NCT02793622 (14) [back to overview]	Mean Gestational Age in Weeks at Birth
NCT02793622 (14) [back to overview]	Number of Participants Who Deliver With a Composite Adverse Birth Outcome
NCT02793622 (14) [back to overview]	Number of Participants With Adverse Events
NCT02793622 (14) [back to overview]	Prevalence of Anemia in Pregnant Women
NCT02793622 (14) [back to overview]	Prevalence of Asymptomatic Parasitemia in Infants
NCT02793622 (14) [back to overview]	Prevalence of Asymptomatic Parasitemia in Pregnant Women
NCT02802501 (20) [back to overview]	Change From Baseline in Methemoglobin/ Total Hemoglobin
NCT02802501 (20) [back to overview]	Time to Relapse of P. Vivax Malaria
NCT02802501 (20) [back to overview]	Time to Parasite Clearance
NCT02802501 (20) [back to overview]	Time to Fever Clearance
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and Primaquine+DHA-PQP
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Primaquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Percentage of Participants With Relapse-free Efficacy at Four Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone
NCT02802501 (20) [back to overview]	Number of Participants With Recrudescence
NCT02802501 (20) [back to overview]	Number of Participants With Electrocardiogram (ECG) Values Outside Clinical Concern Range-QT Interval Corrected Using Fredericia's Formula (QTcF)
NCT02802501 (20) [back to overview]	Number of Participants With Chemistry Values Outside Clinical Concern Range
NCT02802501 (20) [back to overview]	Number of Participants With Gastrointestinal AEs
NCT02802501 (20) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Double-blind Treatment Phase
NCT02802501 (20) [back to overview]	Number of Participants With Hematology Values Outside Clinical Concern Range
NCT02802501 (20) [back to overview]	Number of Participants With Protocol-defined SAE (Hemoglobin Drop)
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Body Temperature Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Pulse Rate Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Respiratory Rate Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT02802501 (20) [back to overview]	Change From Baseline in QT Interval Corrected by Fridericia's Formula (QTcF)

Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs

NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004 (NCT00948896)
Timeframe: Time from randomization until 24 months of age

,,,,,,,

Intervention	incidence per person-year at risk (Number)
	All grade 3-4 adverse events	Grade 3-4 AEs possibly related to study drugs	All serious adverse events	Elevated Temperature	Anemia	Thrombocytopenia	Elevated aspartate aminotransferase	Elevated alanine aminotransferase	Neutropenia	Malnutrition
HIV-exposed & Daily TS	0.659	0.062	0.330	0.206	0.206	0	0.041	0	0	0.021
HIV-exposed & Monthly DP	0.678	0.097	0.194	0.174	0.291	0.058	0.039	0	0	0.039
HIV-exposed & Monthly SP	1.478	0	0.453	0.532	0.631	0.118	0.020	0	0	0.020
HIV-exposed & no Chemoprevention	1.214	NA	0.411	0.431	0.705	0	0.039	0	0	0.020
HIV-unexposed & Daily TS	0.914	0.054	0.196	0.393	0.318	0.061	0.041	0.027	0.014	0
HIV-unexposed & Monthly DP	0.611	0.021	0.091	0.323	0.168	0.035	0.021	0.021	0.007	0
HIV-unexposed & Monthly SP	1.415	0.056	0.364	0.546	0.602	0.119	0.056	0.028	0.042	0
HIV-unexposed & no Chemoprevention	1.159	NA	0.178	0.542	0.384	0.123	0.048	0.027	0.021	0

Intervention	Episode per person year at risk (Number)
	6-24 mo. of Age	6-11 mo. of Age	12-24 mo. of Age
HIV-unexposed & Daily TS	5.21	3.27	6.32
HIV-unexposed & Monthly DP	3.02	1.49	3.88
HIV-unexposed & Monthly SP	6.73	5.51	7.41
HIV-unexposed & no Chemoprevention	6.95	6.41	7.24

Intervention	Incidence per person year at risk (Number)
	All incident episodes of malaria	Complicated malaria	All-cause hospital admissions
HIV-exposed & Daily TS	8.13	0.116	0.186
HIV-exposed & Monthly DP	6.78	0.044	0.089
HIV-exposed & Monthly SP	6.75	0.147	0.318
HIV-exposed & no Chemoprevention	9.08	0.161	0.459
HIV-unexposed & Daily TS	10.90	0.046	0.091
HIV-unexposed & Monthly DP	10.77	0	0.023
HIV-unexposed & Monthly SP	11.98	0.132	0.452
HIV-unexposed & no Chemoprevention	10.85	0.046	0.046

Intervention	Episodes per person year at risk (Number)
	Randomization - 24 mo. of Age	Randomization -16 mo. of Age	17-24 mo. of Age
HIV-exposed & Daily TS	2.86	1.70	3.79
HIV-exposed & Monthly DP	1.83	0.90	2.67
HIV-exposed & Monthly SP	4.50	3.72	5.22
HIV-exposed & no Chemoprevention	6.28	5.42	7.04

Intervention	Positive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	59
3 Dose DP Pregnancy / 3 Monthly DP Infancy	25
3 Dose DP Pregnancy / Monthly DP Infancy	7
Monthly DP Pregnancy / 3 Monthly DP Infancy	52
Monthly DP Pregnancy / Monthly DP Infancy	4

Intervention	Positive specimens (Number)
Mothers - 3 Dose SP	206
Mothers - 3 Dose DP	74
Mothers - Monthly DP	26

Intervention	participants (Number)
	Microscopy	LAMP
Mothers - 3 Dose DP	1	3
Mothers - 3 Dose SP	5	25
Mothers - Monthly DP	0	1

Intervention	events per person years (Number)
Mothers - 3 Dose SP	0.95
Mothers - 3 Dose DP	0.31
Mothers - Monthly DP	0

Intervention	Events per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	0.26
3 Dose DP Pregnancy / 3 Monthly DP Infancy	0.30
3 Dose DP Pregnancy / Monthly DP Infancy	0.00
Monthly DP Pregnancy / 3 Monthly DP Infancy	0.43
Monthly DP Pregnancy / Monthly DP Infancy	0.03

Intervention	Events per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	0.87
3 Dose DP Pregnancy / 3 Monthly DP Infancy	0.88
3 Dose DP Pregnancy / Monthly DP Infancy	0.83
Monthly DP Pregnancy / 3 Monthly DP Infancy	1.24
Monthly DP Pregnancy / Monthly DP Infancy	0.64

Intervention	Events per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	0.043
3 Dose DP Pregnancy / 3 Monthly DP Infancy	0.036
3 Dose DP Pregnancy / Monthly DP Infancy	0.089
Monthly DP Pregnancy / 3 Monthly DP Infancy	0.082
Monthly DP Pregnancy / Monthly DP Infancy	0.043

Intervention	Events per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy	0.022
3 Dose DP Pregnancy / 3 Monthly DP Infancy	0.024
3 Dose DP Pregnancy / Monthly DP Infancy	0.000
Monthly DP Pregnancy / 3 Monthly DP Infancy	0.035
Monthly DP Pregnancy / Monthly DP Infancy	0.000

Intervention	Participants (Count of Participants)
	Micropscopic assessment of placental blood	LAMP assessment of placental blood
Mothers - 3 Dose DP	3	3
Mothers - 3 Dose SP	5	19
Mothers - Monthly DP	0	2

Intervention	Participants (Count of Participants)
TS + DP Placebo Pregnancy	15
Daily TS + Monthly DP Pregnancy	20

Intervention	Participants (Count of Participants)
	Microscopy of placental blood	LAMP analysis of placental blood
Daily TS + Monthly DP Pregnancy	1	3
TS + DP Placebo Pregnancy	0	1

Intervention	Participants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy	28
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy	1

Intervention	episodes per person year (Number)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy	1.98
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy	1.71

Intervention	weeks (Mean)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy	39.4
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy	39.6

Intervention	Percentage of Methemoglobin in total Hb (Mean)
	Day 2, n=48, 50, 50	Day 3, n=48, 50, 50	Day 4, n=48, 50, 50	Day 5, n=48, 50, 50	Day 6, n=46, 49, 50	Day 7, n=48, 50, 50	Day 8, n=46, 48, 48	Day 9, n=46, 47, 47	Day 10, n=47, 45, 49	Day 11, n=47, 44, 49	Day 12, n=47, 47, 50	Day 13, n=48, 48, 48	Day 14, n=48, 50, 50	Day 15, n=17, 22, 14	Day 16, n=43, 48, 47	Day 18, n=46, 48, 49	Day 20, n=42, 49, 48	Day 21, n=43, 48, 48	Day 22, n=45, 49, 48	Day 24, n=41, 46, 47	Day 26, n=44, 45, 47	Day 28, n=47, 50, 50	Day 60, n=47, 50, 49
DHA-PQP Only	-0.13	-0.16	-0.16	-0.18	-0.15	-0.19	-0.12	-0.13	-0.16	-0.13	-0.13	-0.14	-0.18	-0.08	-0.12	-0.12	-0.09	-0.07	-0.13	-0.11	-0.17	-0.15	-0.11
Primaquine+DHA-PQP	-0.06	0.01	0.28	0.62	0.91	1.20	1.41	1.53	1.69	1.82	1.92	2.02	2.01	2.13	1.84	1.29	0.80	0.69	0.49	0.41	0.19	0.08	-0.01
Tafenoquine+ DHA-PQP	-0.07	-0.04	0.06	0.12	0.16	0.19	0.23	0.24	0.24	0.18	0.18	0.18	0.12	0.00	0.12	0.11	0.06	0.03	0.01	0.03	0.03	0.01	-0.07

Intervention	Days (Median)
DHA-PQP Only	81.5
Tafenoquine+ DHA-PQP	96.0
Primaquine+DHA-PQP	NA

Intervention	Hours (Median)
DHA-PQP Only	18.1
Tafenoquine+ DHA-PQP	18.1
Primaquine+DHA-PQP	18.0

artenimol

Description

Cross-References

Synonyms (73)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (3)

Inhibition Measurements

Biological Processes (21)

Molecular Functions (27)

Ceullar Components (3)

Bioassays (807)

Research

Studies (1,453)

Study Types

Clinical Trials (116)

Trial Overview

Trial Outcomes

Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs

Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants

Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk

Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants

Prevalence of Parasitemia in Infants

Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy

Prevalence of Gametocytemia in Pregnant Women

Prevalence of Gametocytemia in Infants

Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery

Prevalence of Anemia in Pregnant Women

Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery

Incidence of Malaria in Pregnant Women

Incidence of Malaria in Infants

Incidence of Malaria in Infants

Incidence of Hospital Admissions in Infants

Incidence of Complicated Malaria in Infants

Prevalence of Placental Malaria

Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP

Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)

Incidence of Malaria, Pregnant Women

Number of Monthly Routine Visits With Positive Blood Samples for Parasites

Number of Participants With Placental Malaria

Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia

Maternal Parasitemia at Delivery by Microscopy and LAMP

Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)

Prevalence of Maternal Malaria

Prevalence of Placental Malaria by Histology

Prevalence of Placental Parasitemia

Prevalence of Anemia in Infants

Incidence of Complicated Malaria in Infants

Incidence of Hospital Admissions in Infants

Incidence of Malaria in Infants

Infant Mortality Rate

Mean Gestational Age in Weeks at Birth

Number of Participants Who Deliver With a Composite Adverse Birth Outcome

Number of Participants With Adverse Events

Prevalence of Anemia in Pregnant Women

Prevalence of Asymptomatic Parasitemia in Infants

Prevalence of Asymptomatic Parasitemia in Pregnant Women

Change From Baseline in Methemoglobin/ Total Hemoglobin

Time to Relapse of P. Vivax Malaria

Time to Parasite Clearance

Time to Fever Clearance

Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and Primaquine+DHA-PQP

Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone

Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Primaquine With DHA-PQP and DHA-PQP Alone

Percentage of Participants With Relapse-free Efficacy at Four Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone

Number of Participants With Recrudescence

Number of Participants With Electrocardiogram (ECG) Values Outside Clinical Concern Range-QT Interval Corrected Using Fredericia's Formula (QTcF)

Number of Participants With Chemistry Values Outside Clinical Concern Range

Number of Participants With Gastrointestinal AEs

Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Double-blind Treatment Phase

Number of Participants With Hematology Values Outside Clinical Concern Range

Number of Participants With Protocol-defined SAE (Hemoglobin Drop)

Number of Participants With Worst Case Body Temperature Results Relative to Normal Range Post-Baseline Relative to Baseline

Number of Participants With Worst Case Pulse Rate Results Relative to Normal Range Post-Baseline Relative to Baseline

Number of Participants With Worst Case Respiratory Rate Results Relative to Normal Range Post-Baseline Relative to Baseline

Intervention	Hours (Median)
DHA-PQP Only	16.5
Tafenoquine+ DHA-PQP	15.8
Primaquine+DHA-PQP	16.8

Intervention	Participants (Count of Participants)
	ALT, High	ALP, High	AST, High	Bilirubin, High	Creatine Kinase, High	Creatinine, High	Indirect bilirubin, High	Urea, High
DHA-PQP Only	1	1	0	4	7	0	1	0
Primaquine+DHA-PQP	0	0	0	4	6	0	1	0
Tafenoquine+ DHA-PQP	3	0	1	6	6	0	1	0

Intervention	Participants (Count of Participants)
	Nausea	Vomiting	Diarrhea	Dyspepsia	Abdominal distension	Abdominal discomfort	Constipation
DHA-PQP Only	5	6	5	2	1	0	0
Primaquine+DHA-PQP	3	1	2	4	1	2	0
Tafenoquine+ DHA-PQP	4	5	2	3	1	0	1

Intervention	Participants (Count of Participants)
	Any AEs	Any SAEs
DHA-PQP Only	41	1
Primaquine+DHA-PQP	34	2
Tafenoquine+ DHA-PQP	41	2

Intervention	Participants (Count of Participants)
	Hemoglobin, Low	Lymphocytes, High	Lymphocytes, Low	Platelets, Low
DHA-PQP Only	0	3	0	0
Primaquine+DHA-PQP	0	2	1	0
Tafenoquine+ DHA-PQP	0	4	0	1

Intervention	Participants (Count of Participants)
	Day 3	Day 5	Day 7	Day 14
DHA-PQP Only	0	0	0	0
Primaquine+DHA-PQP	0	0	0	0
Tafenoquine+ DHA-PQP	0	0	0	0

Intervention	Participants (Count of Participants)
	To Low	To Normal or No change	To High
DHA-PQP Only	42	3	10
Primaquine+DHA-PQP	42	5	6
Tafenoquine+ DHA-PQP	38	7	14

Intervention	Participants (Count of Participants)
	SBP, To Low	SBP, To Normal or No change	SBP, To High	DBP, To Low	DBP, To Normal or No change	DBP, To High
DHA-PQP Only	0	19	31	11	16	28
Primaquine+DHA-PQP	0	25	25	15	16	28
Tafenoquine+ DHA-PQP	1	21	29	9	20	25

Intervention	Milliseconds (Mean)
	Day 3: 4 hours post DHA-PQP dose	Day 7	Day 28
DHA-PQP Only	35.3	11.5	2.4
Primaquine+DHA-PQP	40.8	16.5	10.2
Tafenoquine+ DHA-PQP	44.5	12.2	7.5